


**CUMULATIVE
SUPPLEMENT 4
APRIL 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 4

April 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement.....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend.....	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List.....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution.....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists.....	A-1
B. Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

**CUMULATIVE SUPPLEMENT 4
April 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> (FORMER ABBREVIATED NAME)	<u>NEW APPLICANT NAME</u> (NEW ABBREVIATED NAME)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352			
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)			
MULTISOURCE	13578 (84.1%)	13744 (84.1%)			
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)			
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)			
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	13	22			
NUMBER OF APPLICANTS	927	935			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
FIORICET

@ ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

>D> AA RANBAXY 300MG;30MG A085868 001 Apr CAHN
>D> AA 300MG;60MG A087083 001 Apr CAHN
>A> AA SUN PHARM INDS LTD 300MG;30MG A085868 001 Apr CAHN
>A> AA 300MG;60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG;2.5MG A040846 001 Jun 09, 2010 Feb CTEC
>D> @ RANBAXY LABS LTD 325MG;10MG A040826 001 Aug 16, 2007 Apr CAHN
>A> @ SUN PHARM INDS LTD 325MG;10MG A040826 001 Aug 16, 2007 Apr CAHN
NORCO
AA ACTAVIS LABS FL INC 325MG;2.5MG A040148 004 Jul 07, 2014 Feb NEWA
AA 325MG;5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION
TUDORZA PRESSAIR

>A> + ASTRAZENECA PHARMS 0.375MG/INH N202450 001 Jul 23, 2012 Apr CAHN
>D> + FOREST LABS INC 0.375MG/INH N202450 001 Jul 23, 2012 Apr CAHN

ACYCLOVIR

TABLET;ORAL
ACYCLOVIR

>D> AB RANBAXY 400MG A074980 001 Sep 30, 1998 Apr CAHN
>D> AB 800MG A074980 002 Sep 30, 1998 Apr CAHN
>A> AB SUN PHARM INDS LTD 400MG A074980 001 Sep 30, 1998 Apr CAHN
>A> AB 800MG A074980 002 Sep 30, 1998 Apr CAHN

ADENOSINE

INJECTABLE;INJECTION
ADENOSINE

>D> AP AGILA SPECLTS 3MG/ML A078686 001 May 13, 2009 Apr CAHN
>A> AP MYLAN PHARMS INC 3MG/ML A078686 001 May 13, 2009 Apr CAHN

ALBUTEROL SULFATE

POWDER, METERED;INHALATION
PROAIR RESPICLICK

+ TEVA BRANDED PHARM EQ 0.090MG BASE/INH N205636 001 Mar 31, 2015 Mar NEWA
SYRUP;ORAL

>D> AA ALBUTEROL SULFATE
ACTAVIS MID ATLANTIC EQ 2MG BASE/5ML A074454 001 Sep 25, 1995 Apr CAHN
>A> AA G AND W LABS INC EQ 2MG BASE/5ML A074454 001 Sep 25, 1995 Apr CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ALFUZOSIN HYDROCHLORIDE

@ WOCKHARDT LTD 10MG A090221 001 Aug 10, 2012 Feb DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

>A>	ALOSETRON HYDROCHLORIDE							
>A>	AB	ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr	NEWA
>A>	AB		EQ 1MG BASE	A200652	002	May 04, 2015	Apr	NEWA
		LOTRONEX						
>D>		PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr	CFTG
>A>	AB		EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr	CFTG
>D>		+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr	CFTG
>A>	AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr	CFTG

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar	NEWA
AB			0.5MG	A200739	002	Apr 15, 2015	Mar	NEWA
AB			1MG	A200739	003	Apr 15, 2015	Mar	NEWA
AB			2MG	A200739	004	Apr 15, 2015	Mar	NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan	CAHN
----	--	----------------------	-------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@	IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar	CAHN
@		EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb	DISC
---	-----------------	----------------	---------	-----	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC
---	-----------------	--	---------	-----	--------------	-----	------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB		CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
AB			EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
>D>	AB	RANBAXY	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
>D>	AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
>D>	AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
>A>	AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
>A>	AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

		SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan	NEWA
			EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan	NEWA
		+	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar	NEWA
AB			EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar	NEWA
AB			EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar	NEWA
AB			EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar	NEWA
AB		LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar	NEWA
AB			EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar	NEWA
AB			EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar	NEWA
AB			EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar	NEWA

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>D>	AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
	AB		EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar NEWA
>D>	AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
	AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar NEWA
>D>	AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
	AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar NEWA
>D>	AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
	AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar NEWA
>A>	AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
>A>	AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
>A>	AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
>A>	AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
	AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar NEWA
	AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar NEWA
	AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar NEWA
	AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
	AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
	AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
	AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
	AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
	AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
	AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA
	AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
	AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

>A>	AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
>A>	AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
		NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
>A>	AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

>D>	AB	RANBAXY	250MG	A065016	001	Apr 08, 1999	Apr CAHN
>D>	AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
>A>	AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

>D>		@ RANBAXY	200MG/5ML	A065113	001	Nov 29, 2002	Apr CAHN
>D>		@	400MG/5ML	A065113	002	Nov 29, 2002	Apr CAHN
>A>		@ SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002	Apr CAHN
>A>		@	400MG/5ML	A065113	002	Nov 29, 2002	Apr CAHN

TABLET;ORAL

AMOXICILLIN

>D>	AB	RANBAXY	500MG	A065059	001	Nov 24, 2000	Apr CAHN
>D>	AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr CAHN
>A>	AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

>D>	AB	RANBAXY	125MG	A065021	001	Dec 23, 1999	Apr CAHN
>D>		@	200MG	A065060	001	Nov 29, 2000	Apr CAHN
>D>	AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
>D>		@	400MG	A065060	002	Nov 29, 2000	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr CAHN
>A>		@	200MG	A065060	001	Nov 29, 2000	Apr CAHN
>A>	AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
>A>		@	400MG	A065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	RANBAXY	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr CAHN
>D>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr CAHN
>D>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr	CAHN
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr	CAHN
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr	CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	RANBAXY	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr	CAHN
>D>		@ RANBAXY LABS	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	CAHN
>A>		@ SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	CAHN
>A>	AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr	CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	RANBAXY	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr	CAHN
>D>	AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr	CAHN
>A>	AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr	CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

		ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CTNA
		+	10MG	A200166	002	Aug 09, 2012	Mar	CTNA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

>A>		@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr	CAHN
>D>		@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr	CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

		@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar	CAHN
--	--	------------------------	-----	---------	-----	--------------	-----	------

ARGATROBAN

>A>		INJECTABLE; INJECTION						
>A>		ARGATROBAN						
>A>	AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr	CDFR
>D>		INJECTABLE; IV (INFUSION)						
>D>		ARGATROBAN						
>D>	AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr	CDFR
	AP		250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar	NEWA

ARIPIPIRAZOLE

>D>		SOLUTION;ORAL						
>D>		ABILIFY						
>D>		+ OTSUKA	1MG/ML	N021713	001	Dec 10, 2004	Apr	DISC
>A>		@	1MG/ML	N021713	001	Dec 10, 2004	Apr	DISC
		TABLET;ORAL						
		ABILIFY						
>D>		OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr	CFTG
>A>	AB		2MG	N021436	006	Nov 15, 2002	Apr	CFTG
>D>		+	5MG	N021436	005	Nov 15, 2002	Apr	CFTG
>A>	AB	+	5MG	N021436	005	Nov 15, 2002	Apr	CFTG
>D>		+	10MG	N021436	001	Nov 15, 2002	Apr	CFTG
>A>	AB	+	10MG	N021436	001	Nov 15, 2002	Apr	CFTG
>D>			15MG	N021436	002	Nov 15, 2002	Apr	CFTG
>A>	AB		15MG	N021436	002	Nov 15, 2002	Apr	CFTG
>D>			20MG	N021436	003	Nov 15, 2002	Apr	CFTG
>A>	AB		20MG	N021436	003	Nov 15, 2002	Apr	CFTG
>D>			30MG	N021436	004	Nov 15, 2002	Apr	CFTG
>A>	AB		30MG	N021436	004	Nov 15, 2002	Apr	CFTG
>A>		ARIPIPIRAZOLE						
>A>	AB	ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr	NEWA
>A>	AB		5MG	A202101	002	Apr 28, 2015	Apr	NEWA
>A>	AB		10MG	A202101	003	Apr 28, 2015	Apr	NEWA
>A>	AB		15MG	A202101	004	Apr 28, 2015	Apr	NEWA
>A>	AB		20MG	A202101	005	Apr 28, 2015	Apr	NEWA
>A>	AB		30MG	A202101	006	Apr 28, 2015	Apr	NEWA
>A>	AB	HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr	NEWA
>A>	AB		5MG	A205064	002	Apr 28, 2015	Apr	NEWA

TABLET;ORAL							
ARIPIPIRAZOLE							
>A>	AB		10MG	A205064	003	Apr 28, 2015	Apr NEWA
>A>	AB		15MG	A205064	004	Apr 28, 2015	Apr NEWA
>A>	AB		20MG	A205064	005	Apr 28, 2015	Apr NEWA
>A>	AB		30MG	A205064	006	Apr 28, 2015	Apr NEWA
>A>	AB	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
>A>	AB		5MG	A078607	002	Apr 28, 2015	Apr NEWA
>A>	AB		10MG	A078608	001	Apr 28, 2015	Apr NEWA
>A>	AB		15MG	A078708	001	Apr 28, 2015	Apr NEWA
>A>	AB		20MG	A078708	002	Apr 28, 2015	Apr NEWA
>A>	AB		30MG	A078708	003	Apr 28, 2015	Apr NEWA
>A>	AB	TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
>A>	AB		10MG	A201519	003	Apr 28, 2015	Apr NEWA
>A>	AB		5MG	A201519	002	Apr 28, 2015	Apr NEWA
>A>	AB		15MG	A201519	004	Apr 28, 2015	Apr NEWA
>A>	AB		20MG	A201519	005	Apr 28, 2015	Apr NEWA
>A>	AB		30MG	A201519	006	Apr 28, 2015	Apr NEWA
TABLET, ORALLY DISINTEGRATING;ORAL							
ABILIFY							
>D>	+	OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
>A>	AB	+	10MG	N021729	002	Jun 07, 2006	Apr CFTG
>D>			15MG	N021729	003	Jun 07, 2006	Apr CFTG
>A>	AB		15MG	N021729	003	Jun 07, 2006	Apr CFTG
ARIPIPIRAZOLE							
>A>	AB	ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
>A>	AB		15MG	A202102	002	Apr 28, 2015	Apr NEWA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>							
CAPSULE;ORAL							
FIORINAL							
AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan CAHN
TABLET;ORAL							
FIORINAL							
		@ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CAHN
<u>ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>							
CAPSULE;ORAL							
FIORINAL W/CODEINE							
AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan CAHN
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>							
TABLET;ORAL							
NORGESIC							
		@ MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar DISC
NORGESIC FORTE							
		@ MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar DISC
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE							
		SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar CTEC
	+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar CTEC
<u>ASPIRIN; OXYCODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
OXYCODONE AND ASPIRIN							
AA		ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar CAHN
<u>ATAZANAVIR SULFATE; COBICISTAT</u>							
TABLET;ORAL							
EVOTAZ							
	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan NEWA
<u>ATENOLOL</u>							
TABLET;ORAL							
TENORMIN							
AB		ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
AB			50MG	N018240	001		Feb CAHN
AB	+		100MG	N018240	002		Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

TENORETIC 100

AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
		TENORETIC 50					
AB		ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB			EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB			EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB			EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
>D>	AB	RANBAXY LABS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
>D>	AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
>D>	AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
>D>	AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
>A>	AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
>A>	AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
>A>	AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	--	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP		AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

	+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
		MOTOFEN HALF-STRENGTH					
	@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

	+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb NEWA
--	---	------------	------------------------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB			10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB			20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB			40MG	A076820	004	Feb 03, 2006	Jan CAHN
>D>	AB	RANBAXY	5MG	A076344	001	Feb 11, 2004	Apr CAHN
>D>	AB		10MG	A076344	002	Feb 11, 2004	Apr CAHN
>D>	AB		20MG	A076344	003	Feb 11, 2004	Apr CAHN
>D>	AB		40MG	A076344	004	Feb 11, 2004	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
>A>	AB		10MG	A076344	002	Feb 11, 2004	Apr CAHN
>A>	AB		20MG	A076344	003	Feb 11, 2004	Apr CAHN
>A>	AB		40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	RANBAXY	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
>D>	AB		10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
>D>	AB		20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
>D>	AB		20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN

TABLET;ORAL

BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB		10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
>A>	AB		20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
>A>	AB		20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	APOTEX INC		100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA			200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA	BANNER LIFE SCIENCES		100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA			200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ONEXTON

+	DOW PHARM		3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD
---	-----------	--	--------------------	---------	-----	--------------	----------

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA	NUVO PHARM INC		0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
AA			1MG	A204713	002	Apr 14, 2015	Mar NEWA
AA			2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

>A>	AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
>A>		@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN
>D>	AB	TEVA	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
>D>		@ TEVA PHARMS	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETA-VAL

>A>	AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN
>D>	AB	TEVA	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA		5MG	A091256	001	May 04, 2010	Mar CAHN
AA			10MG	A091256	002	May 04, 2010	Mar CAHN
AA			25MG	A091256	003	May 04, 2010	Mar CAHN
AA			50MG	A091256	004	May 04, 2010	Mar CAHN
AA	LANNETT HOLDINGS INC		5MG	A040703	001	Mar 27, 2008	Feb CMFD
AA			50MG	A040677	001	Mar 27, 2008	Feb CMFD
AA	DUVOID						
AA	WELLSPRING PHARM		10MG	A086262	001		Jan CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

@	BANNER LIFE SCIENCES		75MG	A203174	001	Aug 12, 2014	Jan CAHN
---	----------------------	--	------	---------	-----	--------------	----------

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

>A>	AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
>D>		+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
>A>	AT		0.03%	A203991	001	Feb 20, 2015	Apr CTEC
			0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT			0.03%	A203991	001	Feb 20, 2015	Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT1	PADDOCK LLC		EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan NEWA
-----	-------------	--	---------------	---------	-----	--------------	----------

BUDESONIDEAEROSOL, FOAM;RECTAL
UCERIS

>D>	+	SALIX PHARMS INC	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN
>A>	+	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN
		SPRAY, METERED;NASAL						
		BUDESONIDE						
		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC

BUPRENORPHINE HYDROCHLORIDETABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA
AB			EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb	NEWA
AB		MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb	NEWA
AB			EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb	NEWA

BUPROPION HYDROBROMIDETABLET, EXTENDED RELEASE;ORAL
APLENZIN

		VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
			348MG	N022108	002	Apr 23, 2008	Feb	CAHN
	+		522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB2		SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
-----	--	------------	-------	---------	-----	--------------	-----	------

CALCITONIN SALMONINJECTABLE;INJECTION
CALCITONIN-SALMON

	@	IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar	CAHN
--	---	--------------	-----------	---------	-----	--------------	-----	------

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB		BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
AB			0.5MCG	A091174	002	May 24, 2013	Jan	CAHN
AB		STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan	CAHN
AB			0.5MCG	A091356	002	Dec 12, 2014	Jan	CAHN

CALCIUM ACETATETABLET;ORAL
CALCIUM ACETATE

AB		ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan	NEWA
----	--	----------------------	------------------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+		GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan	CPOT
---	--	--------------------	---	---------	-----	--------------	-----	------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@		GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan	CPOT
---	--	--------------------	--	---------	-----	--------------	-----	------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+		GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan	CPOT
---	--	--------------------	---	---------	-----	--------------	-----	------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+		GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan	CPOT
---	--	--------------------	--	---------	-----	--------------	-----	------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+		GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;	N021703	006	Oct 25, 2006	Jan	CPOT
---	--	--------------------	---	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER		N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)				
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT
PRISMASOL BK 0/0 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	3.68GM/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER						
@	BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390	001		Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438	001			Mar	DISC
---	-----------------	--	---------	-----	--	--	-----	------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B2K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015		Feb	CAIN
---	---------------	--	---------	-----	--------------	--	-----	------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026	001	Jan 13, 2015		Feb	CAIN
---	---------------	--	---------	-----	--------------	--	-----	------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG; 12.5MG	A204100	001	Feb 27, 2015		Feb	NEWA
AB		32MG; 12.5MG	A204100	002	Feb 27, 2015		Feb	NEWA
AB		32MG; 25MG	A204100	003	Feb 27, 2015		Feb	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

>A>	AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr	NEWA
>A>	AB		500MG	A202593	002	Apr 23, 2015	Apr	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>A>	@	G AND W LABS INC	12.5MG	A074462	001	Feb 13, 1996	Apr	CAHN
>A>	@		12.5MG	A074590	004	Aug 30, 1996	Apr	CAHN
>A>	@		25MG	A074462	002	Feb 13, 1996	Apr	CAHN
>A>	@		25MG	A074590	002	Aug 30, 1996	Apr	CAHN
>A>	@		50MG	A074462	003	Feb 13, 1996	Apr	CAHN
>A>	@		50MG	A074590	001	Aug 30, 1996	Apr	CAHN
>A>	@		100MG	A074462	004	Feb 13, 1996	Apr	CAHN
>A>	@		100MG	A074590	003	Aug 30, 1996	Apr	CAHN
>D>	@	IVAX SUB TEVA PHARMS	12.5MG	A074590	004	Aug 30, 1996	Apr	CAHN
>D>	@		25MG	A074590	002	Aug 30, 1996	Apr	CAHN
>D>	@		50MG	A074590	001	Aug 30, 1996	Apr	CAHN
>D>	@		100MG	A074590	003	Aug 30, 1996	Apr	CAHN
>D>	@	TEVA PHARMS	12.5MG	A074462	001	Feb 13, 1996	Apr	CAHN
>D>	@		25MG	A074462	002	Feb 13, 1996	Apr	CAHN
>D>	@		50MG	A074462	003	Feb 13, 1996	Apr	CAHN
>D>	@		100MG	A074462	004	Feb 13, 1996	Apr	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	G AND W LABS INC	25MG; 15MG	A074827	001	Dec 29, 1997	Apr	CAHN
>A>	AB		25MG; 25MG	A074827	002	Dec 29, 1997	Apr	CAHN
>A>	AB		50MG; 15MG	A074827	004	Dec 29, 1997	Apr	CAHN
>A>	AB		50MG; 25MG	A074827	003	Dec 29, 1997	Apr	CAHN
>D>	AB	TEVA	25MG; 15MG	A074827	001	Dec 29, 1997	Apr	CAHN
>D>	AB		25MG; 25MG	A074827	002	Dec 29, 1997	Apr	CAHN
>D>	AB		50MG; 15MG	A074827	004	Dec 29, 1997	Apr	CAHN
>D>	AB		50MG; 25MG	A074827	003	Dec 29, 1997	Apr	CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

IMPAX LABS INC

		23.75MG; 95MG	N203312	001	Jan 07, 2015		Jan	NEWA
		36.25MG; 145MG	N203312	002	Jan 07, 2015		Jan	NEWA
		48.75MG; 195MG	N203312	003	Jan 07, 2015		Jan	NEWA
+		61.25MG; 245MG	N203312	004	Jan 07, 2015		Jan	NEWA

SUSPENSION;ENTERAL
DUOPA

+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA
---	------------	-------------------	---------	-----	--------------	----------

CARVEDILOLTABLET;ORAL
CARVEDILOL

>D>	AB	RANBAXY	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
>D>	AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
>D>	AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
>D>	AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
>A>	AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
>A>	AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
>A>	AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION;ORAL
CEFADROXIL

>D>		RANBAXY	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
>D>	AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
>D>	AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
>A>	AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
>A>	AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUMINJECTABLE;INJECTION
CEFAZOLIN SODIUM

AP		FACTA FARMA	EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP			EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN
AP			EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN

CEFIXIMEFOR SUSPENSION;ORAL
CEFIXIME

>A>	AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
>A>	AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
>D>		LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
>A>	AB		100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
>D>			200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG
>A>	AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUMINJECTABLE;INJECTION
CEFOTAN

@	IGI LABS INC	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN
@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETILFOR SUSPENSION;ORAL
CEFPODOXIME PROXETIL

>D>	AB	RANBAXY	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
>D>	AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
>A>	AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

>D>	AB	RANBAXY	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
>D>	AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
>A>	AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTRIAZONE SODIUMINJECTABLE; INJECTION
CEFTRIAZONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan	CAHN
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS						
	CEFTRIAZONE						
	@ FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan	CAHN

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFUROXIME AXETIL

>D>	AB	RANBAXY	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr	CAHN
>D>	AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr	CAHN
>A>	AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr	CAHN

TABLET; ORAL

CEFUROXIME AXETIL

>D>	AB	RANBAXY	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr	CAHN
>D>	AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr	CAHN
>D>	AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr	CAHN
>A>	AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr	CAHN
>A>	AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr	CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION
CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan	CAHN
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS						
	CEFUROXIME SODIUM						
AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan	CAHN

CELECOXIBCAPSULE; ORAL
CELECOXIB

AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan	NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan	NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan	NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan	NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan	NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan	NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan	NEWA

CEPHALEXINCAPSULE; ORAL
CEPHALEXIN

>D>	AB	RANBAXY	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr	CAHN
>D>	AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr	CAHN
>A>	AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr	CAHN

FOR SUSPENSION; ORAL

CEPHALEXIN

>D>	@	RANBAXY	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr	CAHN
>D>	@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr	CAHN
>A>	@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr	CAHN
>A>	@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr	CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A206438	001	Jan 27, 2015	Jan	NEWA
	VITUZ						
AA	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Jan	CFTG

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

>A> TUZISTRA XR

>A>	+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr	NEWA
-----	---	-----------------	---	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ EUROHLTH INTL SARL 25MG/ML

A083329 001 Feb CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

>A>		@ G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr	CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar	CMFD
>D>		@ TEVA	50MG	A088651	001	May 30, 1985	Apr	CAHN

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

>D>		ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Apr	CAHN
			50MG	N205750	001	Mar 17, 2015	Mar	NEWA
>D>	+		250MG	N205750	002	Mar 17, 2015	Apr	CAHN
	+		250MG	N205750	002	Mar 17, 2015	Mar	NEWA
>A>		RTRX	50MG	N205750	001	Mar 17, 2015	Apr	CAHN
>A>	+		250MG	N205750	002	Mar 17, 2015	Apr	CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

>D>		@ ACTAVIS MID ATLANTIC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr	CAHN
>A>		@ G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr	CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

>D>	AP	CLARIS LIFESCIENCES	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr	CAHN
>D>	AP		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr	CAHN
>A>	AP	CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr	CAHN
>A>	AP		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr	CAHN
		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	CLARIS LIFESCIENCES	200MG/100ML	A078024	001	Mar 18, 2008	Apr	CAHN
>D>	AP		400MG/200ML	A078024	002	Mar 18, 2008	Apr	CAHN
>A>	AP	CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr	CAHN
>A>	AP		400MG/200ML	A078024	002	Mar 18, 2008	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

>D>	AB	RANBAXY	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr	CAHN
>D>	AB		EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr	CAHN
>D>	AB		EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr	CAHN
>A>	AB		EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr	CAHN
>A>	AB		EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr	CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb	NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb	NEWA
AP			EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb	NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

>A>	AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	CAHN
>A>	AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	CAHN
>A>	AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	CAHN

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB	TEVA PHARMS	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	CAHN
>D>	AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	CAHN
>D>	AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

>D>	AB	RANBAXY	125MG/5ML	A065382	001	Aug 30, 2007	Apr	CAHN
>D>	AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr	CAHN
>A>	AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr	CAHN

TABLET;ORAL

CLARITHROMYCIN

>D>	AB	RANBAXY	250MG	A065174	001	Sep 24, 2004	Apr	CAHN
>D>	AB		500MG	A065174	002	Sep 24, 2004	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr	CAHN
>A>	AB		500MG	A065174	002	Sep 24, 2004	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

@ ABBVIE

CLARITHROMYCIN

	AB	+ TEVA	500MG	N050775	001	Mar 03, 2000	Jan	DISC
				A065154	001	May 18, 2005	Jan	CRLD

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

>A>	AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	CAHN
>A>	AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	CAHN
>D>	AB	RANBAXY	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr	CAHN
>D>	AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr	CAHN
>A>	AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr	CAHN
>D>	AB	TEVA	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	CAHN
>D>	AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

@ IGI LABS INC

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ BOCA PHARMA LLC

EQ 1% BASE

EQ 150MG BASE/ML

EQ 150MG BASE

EQ 300MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

CLOBETASOL PROPIONATE

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

	AB	G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb	CAHN
--	----	------------------	-------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

	AT	G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar	CMFD
--	----	------------------	-------	---------	-----	--------------	-----	------

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

	AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar	CAHN
	AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar	CAHN
	AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar	CAHN

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

>D>	AB	RANBAXY	3.75MG	A076911	001	Sep 29, 2004	Apr	CAHN
>D>	AB		7.5MG	A076911	002	Sep 29, 2004	Apr	CAHN
>D>	AB		15MG	A076911	003	Sep 29, 2004	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr	CAHN
>A>	AB		7.5MG	A076911	002	Sep 29, 2004	Apr	CAHN
>A>	AB		15MG	A076911	003	Sep 29, 2004	Apr	CAHN

COBICISTAT; DARUNAVIR ETHANOLATETABLET; ORAL
PREZCOBIX

+ JANSSEN PRODS 150MG;EQ 800MG BASE N205395 001 Jan 29, 2015 Jan NEWA

CODEINE SULFATESOLUTION; ORAL
CODEINE SULFATE

@ ROXANE 30MG/5ML N202245 001 Jun 30, 2011 Jan DISC

COLCHICINECAPSULE; ORAL
MITIGARE

HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014 Jan CAHN

CYANOCOBALAMININJECTABLE; INJECTION
CYANOCOBALAMIN

@ EUROHLTH INTL SARL 1MG/ML A080515 002 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDETABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB	RANBAXY	5MG	A078722	001	May 12, 2008	Apr	CAHN
>D>	AB		7.5MG	A078722	002	May 12, 2008	Apr	CAHN
>D>	AB		10MG	A078722	003	May 12, 2008	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr	CAHN
>A>	AB		7.5MG	A078722	002	May 12, 2008	Apr	CAHN
>A>	AB		10MG	A078722	003	May 12, 2008	Apr	CAHN

DABRAFENIB MESYLATECAPSULE; ORAL
TAFINLAR

		NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar	CAHN
+			EQ 75MG BASE	N202806	002	May 29, 2013	Mar	CAHN

DALTEPARIN SODIUMINJECTABLE; INJECTION
FRAGMIN

>D>		@ EISAI INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr	CAHN
>A>		@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr	CAHN

INJECTABLE; SUBCUTANEOUS
FRAGMIN

>D>		EISAI INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr	CAHN
>D>			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr	CAHN
>D>			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr	CAHN
>D>		@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr	CAHN
>D>			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr	CAHN
>D>			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr	CAHN
>D>			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr	CAHN
>D>			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr	CAHN
>D>		+	95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr	CAHN
>D>		@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr	CAHN
>A>		PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr	CAHN
>A>			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr	CAHN
>A>			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr	CAHN
>A>		@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr	CAHN
>A>			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr	CAHN
>A>			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr	CAHN
>A>			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr	CAHN
>A>			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr	CAHN
>A>		+	95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr	CAHN
>A>		@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr	CAHN

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

AB		ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar	NEWA
AB			EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar	NEWA
		ENABLEX						
AB		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar	CFTG

TABLET, EXTENDED RELEASE;ORAL									
ENABLEX									
AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar	CFTG	
<u>DECITABINE</u>									
INJECTABLE;INTRAVENOUS									
DACOGEN									
AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan	CAHN	
<u>DEFERASIROX</u>									
TABLET;ORAL									
JADENU									
		NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar	NEWA	
			180MG	N206910	002	Mar 30, 2015	Mar	NEWA	
	+		360MG	N206910	003	Mar 30, 2015	Mar	NEWA	
>A>	<u>DEOXYCHOLIC ACID</u>								
>A>	SOLUTION;SUBCUTANEOUS								
>A>	KYBELLA								
>A>	+	KYATHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr	NEWA	
<u>DESMOPRESSIN ACETATE</u>									
TABLET;ORAL									
DDAVP									
AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan	CAHN	
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan	CAHN	
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>									
TABLET;ORAL-28									
KARIVA									
>D>	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC	
>A>	AB	+	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC	
KIMIDESS									
>A>	AB	VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr	NEWA	
<u>DESOXIMETASONE</u>									
OINTMENT;TOPICAL									
DESOXIMETASONE									
>A>	AB	PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr	NEWA	
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>									
INJECTABLE;INJECTION									
DEXAMETHASONE SODIUM PHOSPHATE									
>D>	AP	AGILA SPECLTS	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	Apr	CAHN	
>D>	AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	Apr	CAHN	
		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN	
	AP	+	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb	CAHN	
>A>	AP	MYLAN PHARMS INC	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	Apr	CAHN	
>A>	AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	Apr	CAHN	
<u>DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>									
OINTMENT;OPHTHALMIC									
MAXITROL									
AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar	CAHN	
SUSPENSION/DROPS;OPHTHALMIC									
MAXITROL									
AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar	CAHN	
<u>DEXMEDETOMIDINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
PRECEDEX									
		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan	NEWA	
<u>DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE</u>									
INJECTABLE;INJECTION									
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER									
		@ BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;36 8MG/100ML;526MG/100ML;502MG/100ML	N017451	001		Mar	DISC	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUMINJECTABLE; INJECTION
MD-76R

AP	+	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Feb	CAHN
		SOLUTION; ORAL, RECTAL						
		MD-GASTROVIEW						

AA		LIEBEL-FLARSHEIM	66%;10%	A087388	001		Jan	CAHN
----	--	------------------	---------	---------	-----	--	-----	------

DIETHYLPROPION HYDROCHLORIDETABLET; ORAL
TENUATE

AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		TENUATE DOSPAN						

AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN
----	---	---------------------	------	---------	-----	--	-----	------

DIFLUNISALTABLET; ORAL
DIFLUNISAL

AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

DIGOXININJECTABLE; INJECTION
DIGOXIN

AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb	CAHN
----	--	--------------------	-----------	---------	-----	--	-----	------

TABLET; ORAL
DIGOXIN

AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan	CTEC
AB			0.25MG	A040282	002	Dec 23, 1999	Jan	CTEC
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb	CMFD
AB			0.25MG	A076363	002	Jan 31, 2003	Feb	CMFD

LANOXIN

>A>		CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr	CAHN
>A>	AB		0.125MG	N020405	002	Sep 30, 1997	Apr	CAHN
>A>			0.1875MG	N020405	003	Sep 30, 1997	Apr	CAHN
>A>	AB	+	0.25MG	N020405	004	Sep 30, 1997	Apr	CAHN
>A>		@	0.375MG	N020405	005	Sep 30, 1997	Apr	CAHN
>A>		@	0.5MG	N020405	006	Sep 30, 1997	Apr	CAHN
>D>		COVIS PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Apr	CAHN
>D>	AB		0.125MG	N020405	002	Sep 30, 1997	Apr	CAHN
>D>			0.1875MG	N020405	003	Sep 30, 1997	Apr	CAHN
>D>	AB	+	0.25MG	N020405	004	Sep 30, 1997	Apr	CAHN
>D>		@	0.375MG	N020405	005	Sep 30, 1997	Apr	CAHN
>D>		@	0.5MG	N020405	006	Sep 30, 1997	Apr	CAHN

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILACOR XR

		@ ACTAVIS LABS UT INC	120MG	N020092	001	May 29, 1992	Mar	CAHN
		@	180MG	N020092	002	May 29, 1992	Mar	CAHN
		@	240MG	N020092	003	May 29, 1992	Mar	CAHN
		@ WATSON LABS	120MG	N020092	001	May 29, 1992	Feb	DISC
		@	180MG	N020092	002	May 29, 1992	Feb	DISC
		@	240MG	N020092	003	May 29, 1992	Feb	DISC

DILTIAZEM HYDROCHLORIDE

AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb	CRLD
		TIAZAC						

AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>D>		@ AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Apr	CAHN
>A>		@ MYLAN PHARMS INC	5MG/ML	A075375	001	Sep 30, 1999	Apr	CAHN

DIPYRIDAMOLEINJECTABLE; INJECTION
DIPYRIDAMOLE

>D>	@ AGILA SPECLTS	5MG/ML	A075769	001	Nov 27, 2002	Apr	CAHN
>A>	@ MYLAN PHARMS INC	5MG/ML	A075769	001	Nov 27, 2002	Apr	CAHN

DISULFIRAMTABLET; ORAL
DISULFIRAM

AB	MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb	NEWA
AB		500MG	A203916	002	Mar 04, 2015	Feb	NEWA

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

@ IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN
----------------	-------------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDETABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
AB		10MG	A203034	002	Jan 30, 2015	Jan	NEWA
>D> AB	RANBAXY	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
>D> AB		10MG	A076786	002	Nov 26, 2010	Apr	CAHN
>A> AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
>A> AB		10MG	A076786	002	Nov 26, 2010	Apr	CAHN

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
NAMZARIC

FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Mar	CAHN
+	10MG;28MG	N206439	002	Dec 23, 2014	Mar	CAHN

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

@ IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar	CAHN
@	40MG/ML	N018656	001	Jun 28, 1983	Mar	CAHN
@	80MG/ML	A070089	001	Oct 23, 1985	Mar	CAHN
@	80MG/ML	A070090	001	Oct 23, 1985	Mar	CAHN
@	80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN
@	160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN
@	160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN
@	160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN

DOXEPIIN HYDROCHLORIDECAPSULE; ORAL
DOXEPIIN HYDROCHLORIDE

AB	+ MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+ PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD
	CREAM; TOPICAL ZONALON						
	+ DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

>A> AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA
--------	-----------	--------------------	---------	-----	--------------	-----	------

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

>D> AB	RANBAXY	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
>D> AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
>D> AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN
>A> AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
>A> AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
>A> AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN

TABLET;ORALDOXYCYCLINE

>D>	AB	RANBAXY	EQ 50MG BASE	A065356	001	May 31, 2006	Apr CAHN
>D>	AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr CAHN
>D>	AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr CAHN
>A>	AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr CAHN
>A>	AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr CAHN

DROPERIDOLINJECTABLE; INJECTIONDROPERIDOL

	@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
	@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
	@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOLTABLET;ORAL-28DROSPIRENONE AND ETHINYL ESTRADIOL

>A>	AB	FAMY CARE LTD	3MG;0.03MG	A202131	001	May 04, 2015	Apr NEWA
-----	----	---------------	------------	---------	-----	--------------	----------

ECONAZOLE NITRATECREAM; TOPICALECONAZOLE NITRATE

AB		FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+	PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATETABLET;ORALSAVAYSA

		DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
			EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA
	+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDEINJECTABLE; INJECTIONENLON

	+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD
		TENSILON					
>A>		@ IGI LABS INC	10MG/ML	N007959	001		Apr CAHN
>D>		@ VALEANT PHARMS	10MG/ML	N007959	001		Apr CAHN
		@	10MG/ML	N007959	001		Mar DISC
		TENSILON PRESERVATIVE FREE					
>A>		@ IGI LABS INC	10MG/ML	N007959	002		Apr CAHN
>D>		@ VALEANT PHARMS	10MG/ML	N007959	002		Apr CAHN
		@	10MG/ML	N007959	002		Mar DISC

ELTROMBOPAG OLAMINETABLET;ORALPROMACTA

		NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
			EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN
	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar CAHN
			EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar CAHN
			EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar CAHN

EMPAGLIFLOZIN; LINAGLIPTINTABLET;ORALGLYXAMBI

		BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015	Jan NEWA
	+		25MG;5MG	N206073	002	Jan 30, 2015	Jan NEWA

ENALAPRIL MALEATETABLET;ORALENALAPRIL MALEATE

>D>		@ RANBAXY	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
>D>		@	5MG	A075556	002	Aug 22, 2000	Apr CAHN
>D>		@	10MG	A075556	003	Aug 22, 2000	Apr CAHN
>D>		@	20MG	A075556	004	Aug 22, 2000	Apr CAHN
AB		SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB			5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB			10MG	A075459	001	Aug 22, 2000	Mar CMFD

TABLET;ORAL

ENALAPRIL MALEATE

AB		20MG	A075459	002	Aug 22, 2000	Mar	CMFD
>A>	@ SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr	CAHN
>A>	@	5MG	A075556	002	Aug 22, 2000	Apr	CAHN
>A>	@	10MG	A075556	003	Aug 22, 2000	Apr	CAHN
>A>	@	20MG	A075556	004	Aug 22, 2000	Apr	CAHN
	VASOTEC						
>D>	AB VALEANT INTL	2.5MG	N018998	005	Jul 26, 1988	Apr	CAHN
>D>	AB	5MG	N018998	001	Dec 24, 1985	Apr	CAHN
>D>	AB	10MG	N018998	002	Dec 24, 1985	Apr	CAHN
>D>	AB +	20MG	N018998	003	Dec 24, 1985	Apr	CAHN
>A>	AB VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr	CAHN
>A>	AB	5MG	N018998	001	Dec 24, 1985	Apr	CAHN
>A>	AB	10MG	N018998	002	Dec 24, 1985	Apr	CAHN
>A>	AB +	20MG	N018998	003	Dec 24, 1985	Apr	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>A>	AB G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	CAHN
>A>	AB	10MG;25MG	A075727	002	Sep 18, 2001	Apr	CAHN
>D>	AB TEVA	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	CAHN
>D>	AB	10MG;25MG	A075727	002	Sep 18, 2001	Apr	CAHN

ERGOCALCIFEROL

CAPSULE;ORAL

VITAMIN D

AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan	CAHN
----	----------------------	-----------	---------	-----	--	-----	------

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

>D>	@ BARR	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr	CAHN
>D>	@	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr	CAHN
>A>	@ G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr	CAHN
>A>	@	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr	CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

>A>	AB MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr	NEWA
>A>	AB	EQ 10MG BASE	A077550	002	May 14, 2015	Apr	NEWA
>A>	AB	EQ 20MG BASE	A077550	003	May 14, 2015	Apr	NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP	LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb	NEWA
----	----------	---------	---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan	NEWA
AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan	NEWA
	NEXIUM						
AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan	CFTG
AB	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan	CFTG

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN
	MINIVELLE						
	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jan	NEWA

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

AB	VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan CMFD
AB		400MG	A075095	002	Nov 30, 1999	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

ASHLYNA

AB	GLENMARK GENERICS	0.03MG, 0.01MG; 0.15MG, N/A	A203163	001	Feb 23, 2015	Feb NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
>A>	FAMY CARE LTD	0.03MG; 0.15MG	A200490	001	Apr 21, 2015	Apr NEWA
AB	GLENMARK GENERICS	0.02MG; 0.09MG	A202791	001	Apr 09, 2015	Mar NEWA
AB	+ WATSON LABS	0.02MG; 0.09MG	A079218	001	Jun 06, 2011	Mar CTEC

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

	@ JANSSEN PHARMS	0.035MG/24HR; 0.15MG/24HR	N021180	001	Nov 20, 2001	Feb DISC
	XULANE					
AB	+ MYLAN TECHNOLOGIES	0.035MG/24HR; 0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

	@ ACTAVIS LABS UT INC	0.035MG; 0.5MG	N017566	001		Mar CAHN
	NORINYL 1+35 21-DAY					
AB	ACTAVIS LABS UT INC	0.035MG; 1MG	N017565	001		Feb CAHN
	TRI-NORINYL 21-DAY					
	@ ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	001	Apr 13, 1984	Feb CAHN

TABLET; ORAL-28

BREVICON 28-DAY

AB	ACTAVIS LABS UT INC	0.035MG; 0.5MG	N017743	001		Mar CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL					
>A>	FAMY CARE LTD	0.035MG; 0.4MG	A200897	001	May 11, 2015	Apr NEWA
	NORINYL 1+35 28-DAY					
AB	ACTAVIS LABS UT INC	0.035MG; 1MG	N017565	002		Feb CAHN
	TRI-NORINYL 28-DAY					
AB	+ ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	002	Apr 13, 1984	Feb CAHN

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	FAMY CARE LTD	0.035MG; 0.4MG	A202086	001	Apr 01, 2015	Mar NEWA
----	---------------	----------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

AB	WARNER CHILCOTT LLC	0.0025MG; 0.5MG	N021065	001	Jan 14, 2005	Mar CTEC
	LARIN 24 FE					
AB	NOVAST LABS LTD	0.02MG; 1MG	A202994	001	Feb 18, 2015	Feb NEWA
	LOESTRIN 24 FE					
	@ WARNER CHILCOTT	0.02MG; 1MG	N021871	001	Feb 17, 2006	Jan DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
AB	+ BARR LABS INC	0.005MG; 1MG	A076221	001	Nov 06, 2009	Mar CTEC
AB	GLENMARK GENERICS	0.0025MG; 0.5MG	A203038	001	Apr 02, 2015	Mar NEWA
AB		0.005MG; 1MG	A203038	002	Apr 02, 2015	Mar NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	+ AMNEAL PHARMS	0.02MG; 1MG	A078267	001	Sep 01, 2009	Jan CRLD
	TABLET; ORAL-21					
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
AB	FAMY CARE LTD	0.03MG; 1.5MG	A202770	001	Feb 19, 2015	Feb NEWA

TABLET;ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
 AB FAMY CARE LTD 0.03MG;1.5MG A202741 001 Feb 20, 2015 Feb NEWA

ETHINYL ESTRADIOL; NORGESTIMATETABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL
 AB OC PHARMA 0.035MG;0.035MG;0.035MG;0.18MG;0.2 A200383 001 Apr 07, 2015 Mar NEWA
 15MG;0.25MG
 AB 0.035MG;0.25MG A200384 001 Apr 07, 2015 Mar NEWA

ETHINYL ESTRADIOL; NORGESTRELTABLET;ORAL-28

LOW-OGESTREL-28
 AB WATSON LABS 0.03MG;0.3MG A075288 002 Jul 28, 1999 Feb CMFD

ETHOSUXIMIDECAPSULE;ORAL

ETHOSUXIMIDE
 AB BANNER LIFE SCIENCES 250MG A040430 001 Oct 28, 2002 Jan CAHN

ETOMIDATEINJECTABLE;INJECTIONETOMIDATE

>D> AP AGILA SPECLTS 2MG/ML A078289 001 Jan 02, 2009 Apr CAHN
 >A> AP MYLAN PHARMS INC 2MG/ML A078289 001 Jan 02, 2009 Apr CAHN

FAMOTIDINETABLET;ORAL

PEPCID
 AB VALEANT PHARMS NORTH 20MG N019462 001 Oct 15, 1986 Feb CAHN
 AB + 40MG N019462 002 Oct 15, 1986 Feb CAHN

FELODIPINETABLET, EXTENDED RELEASE;ORALFELODIPINE

>D> AB RANBAXY LABS LTD 2.5MG A091200 001 Dec 13, 2013 Apr CAHN
 >D> AB 5MG A091200 002 Dec 13, 2013 Apr CAHN
 >D> AB 10MG A091200 003 Dec 13, 2013 Apr CAHN
 >A> AB SUN PHARM INDS LTD 2.5MG A091200 001 Dec 13, 2013 Apr CAHN
 >A> AB 5MG A091200 002 Dec 13, 2013 Apr CAHN
 >A> AB 10MG A091200 003 Dec 13, 2013 Apr CAHN

FENOFIBRATECAPSULE;ORALFENOFIBRATE

>D> AB RANBAXY LABS LTD 43MG A201748 001 Oct 31, 2014 Apr CAHN
 >D> AB 130MG A201748 002 Oct 31, 2014 Apr CAHN
 >A> AB SUN PHARM INDS LTD 43MG A201748 001 Oct 31, 2014 Apr CAHN
 >A> AB 130MG A201748 002 Oct 31, 2014 Apr CAHN

TABLET;ORALFENOFIBRATE

>D> AB RANBAXY 54MG A076635 001 Oct 31, 2005 Apr CAHN
 >D> 107MG A076635 002 Oct 31, 2005 Apr CAHN
 >D> AB 160MG A076635 003 Oct 31, 2005 Apr CAHN
 >A> AB SUN PHARM INDS LTD 54MG A076635 001 Oct 31, 2005 Apr CAHN
 >A> 107MG A076635 002 Oct 31, 2005 Apr CAHN
 >A> AB 160MG A076635 003 Oct 31, 2005 Apr CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMALFENTANYL-100

AB ACTAVIS LABS UT INC 100MCG/HR A076709 004 Aug 20, 2007 Mar CAHN
 FENTANYL-25

AB ACTAVIS LABS UT INC 25MCG/HR A076709 001 Aug 20, 2007 Mar CAHN
 FENTANYL-50

AB ACTAVIS LABS UT INC 50MCG/HR A076709 002 Aug 20, 2007 Mar CAHN
 FENTANYL-75

AB ACTAVIS LABS UT INC 75MCG/HR A076709 003 Aug 20, 2007 Mar CAHN

FENTANYL CITRATEFILM;BUCCAL
ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN
----	---	--------------------	-------------------	---------	-----	--------------	-----	------

FENTANYL HYDROCHLORIDESYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

>D>	@	INCLINE THERAP	10.8MCG	N021338	001	May 22, 2006	Apr	CAHN
>A>	@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr	CAHN

FERRIC CITRATE

TABLET;ORAL

AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan	CTNA
---	-----------------	---------------	---------	-----	--------------	-----	------

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)

TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan	NEWA
---	----------------------	----------------------------------	---------	-----	--------------	-----	------

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

>A>	AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
>A>	AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
>A>	AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
>D>	AB	BARR	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
>D>	AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
>D>	AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
>D>	AB	RANBAXY	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
>D>	AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
>D>	AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
>A>	AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
>A>	AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

>D>	AB	RANBAXY	50MG/5ML	A076332	001	Jul 29, 2004	Apr	CAHN
>D>	AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr	CAHN
>A>	AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr	CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr	CAHN
>D>	@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr	CAHN
>D>	AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr	CAHN
>D>	AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr	CAHN
>A>	AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr	CAHN
>A>	AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr	CAHN
>A>	@	MYLAN PHARMS INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr	CAHN
>A>	@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr	CAHN
>D>	AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr	CAHN
>D>	AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr	CAHN
>A>	AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr	CAHN
>A>	AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr	CAHN
>D>	@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr	CAHN
>D>	@		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr	CAHN
>D>	AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr	CAHN
>D>	AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr	CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	NEWA
>A>		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	CAHN
>A>	AP	200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr	CAHN
>A>	AP	400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr	CAHN
>A>	@ MYLAN PHARMS INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr	CAHN
>A>	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F 18

>A>	AP	BIOMEDCL RES FDN	20-300mCi/ML	A203710	001	May 01, 2015	Apr	NEWA
>A>	AP		20-300mCi/ML	A203837	001	May 01, 2015	Apr	NEWA
		UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015	Jan	NEWA
		FLUDEOXYGLUCOSE F18						
>A>	AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr	NEWA
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	NEWA
>A>		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

>D>	AP	AGILA SPECLTS	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Apr	CAHN
>D>	AP	+	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Apr	CAHN
>D>		@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	CAHN
>D>		@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	CAHN
>A>		@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	CAHN
>A>		@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	CAHN
>A>	AP	MYLAN PHARMS INC	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Apr	CAHN
>A>	AP	+	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Apr	CAHN

FLUOCINONIDE

GEL; TOPICAL

FLUOCINONIDE

>A>	AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr	CAHN
>D>	AB	TEVA	0.05%	A072537	001	Feb 07, 1989	Apr	CAHN

FLUOROURACIL

CREAM; TOPICAL

CARAC

>D>		+ VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr	CFTG
>A>	AB	+	0.5%	N020985	001	Oct 27, 2000	Apr	CFTG
		+	0.5%	N020985	001	Oct 27, 2000	Feb	CAHN

FLUOROURACIL

>A>	AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr	NEWA
-----	----	------------------	------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

>A>	AP	MYLAN PHARMS INC	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CAHN
>A>	AP		500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CAHN
>D>	AP	ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CAHN
>D>	AP		500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

		@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
		@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
		+ MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
			EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
>D>	AB	RANBAXY	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN
		@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
		@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
	AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
	AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
	AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
>A>	AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN
		SARAFEM						
		@ ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Mar	DISC
		@	EQ 20MG BASE	N018936	008	Jul 06, 2000	Mar	DISC

FLUPHENAZINE DECANOATEINJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

>D>	@	AGILA SPECLTS	25MG/ML	A075918	001	Aug 17, 2001	Apr	CAHN
>A>	@	MYLAN PHARMS INC	25MG/ML	A075918	001	Aug 17, 2001	Apr	CAHN

FLURANDRENOLIDETAPE; TOPICAL
CORDRAN

+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001			Mar	CAHN
---	---------------------	---------------	---------	-----	--	--	-----	------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREQ ELLIPTA

>A>		GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA
-----	--	---------------	-------------------------------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	RANBAXY	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
>D>	AB		20MG;12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
>A>	AB		20MG;12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

@	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar	CAHN
@		10MG/ML	A070096	001	Sep 09, 1985	Mar	CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

>D>	AB	RANBAXY	100MG	A076606	001	Oct 07, 2005	Apr	CAHN
>D>	AB		300MG	A076606	002	Oct 07, 2005	Apr	CAHN
>D>	AB		400MG	A076606	003	Oct 07, 2005	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr	CAHN
>A>	AB		300MG	A076606	002	Oct 07, 2005	Apr	CAHN
>A>	AB		400MG	A076606	003	Oct 07, 2005	Apr	CAHN

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb	CAHN	
+		1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb	CAHN	
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb	CAHN	
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb	CAHN	
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb	CAHN	
	OPTIMARK IN PLASTIC CONTAINER							
+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb	CAHN	
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb	CAHN	
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb	CAHN	
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb	CAHN	

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

>D>	AB	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr	DISC
>A>		@	1MG	A078952	001	Aug 01, 2013	Apr	DISC
>D>	AB		2MG	A078952	002	Aug 01, 2013	Apr	DISC
>A>		@	2MG	A078952	002	Aug 01, 2013	Apr	DISC
>D>	AB		4MG	A078952	003	Aug 01, 2013	Apr	DISC
>A>		@	4MG	A078952	003	Aug 01, 2013	Apr	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

>D>	AA	RANBAXY	1MG	A040844	001	Aug 18, 2009	Apr	CAHN
>D>	AA		2MG	A040844	002	Aug 18, 2009	Apr	CAHN
>A>	AA	SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr	CAHN
>A>	AA		2MG	A040844	002	Aug 18, 2009	Apr	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>D>		@ APOTEX INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr	CAHN
>D>		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr	CAHN
	AP	BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan	CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan	CAHN
>A>		@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr	CAHN
>A>		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr	CAHN
			GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
	AP	BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>D>	AP	AGILA SPECLTS	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	Apr	CAHN
>D>		@ APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	CAHN
>A>		@ CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	CAHN
>A>	AP	MYLAN PHARMS INC	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	Apr	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

	AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb	CRLD
	AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb	CRLD

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

MICROZIDE

	AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb	CAHN
--	----	---	---------------------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

>D>	AB	RANBAXY	12.5MG;10MG	A076007	001	Jul 01, 2002	Apr	CAHN	
>D>	AB		12.5MG;20MG	A076007	002	Jul 01, 2002	Apr	CAHN	
>D>	AB		25MG;20MG	A076007	003	Jul 01, 2002	Apr	CAHN	
>A>	AB	SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002	Apr	CAHN	
>A>	AB		12.5MG;20MG	A076007	002	Jul 01, 2002	Apr	CAHN	
>A>	AB		25MG;20MG	A076007	003	Jul 01, 2002	Apr	CAHN	
			ZESTORETIC						
	AB		ALVOGEN IPCO SARL	12.5MG;10MG	N019888	003	Nov 18, 1993	Feb	CAHN
	AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Feb	CAHN
	AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Feb	CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	RANBAXY	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr	CAHN
>D>	AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr	CAHN
>D>	AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr	CAHN
>A>	AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr	CAHN
>A>	AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

>A>		+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr	CAHN
>A>				15MG	N202880	002	Oct 25, 2013	Apr	CAHN
>A>				20MG	N202880	003	Oct 25, 2013	Apr	CAHN
>A>				30MG	N202880	004	Oct 25, 2013	Apr	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER

>A>		40MG	N202880	005	Oct 25, 2013	Apr	CAHN	
>A>		50MG	N202880	006	Oct 25, 2013	Apr	CAHN	
>D>	+	ZOGENIX INC	10MG	N202880	001	Oct 25, 2013	Apr	CAHN
>D>		15MG	N202880	002	Oct 25, 2013	Apr	CAHN	
>D>		20MG	N202880	003	Oct 25, 2013	Apr	CAHN	
>D>		30MG	N202880	004	Oct 25, 2013	Apr	CAHN	
>D>		40MG	N202880	005	Oct 25, 2013	Apr	CAHN	
>D>		50MG	N202880	006	Oct 25, 2013	Apr	CAHN	

TABLET, EXTENDED RELEASE;ORAL
HYSINGLA

	+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar	CRLD
--	---	------------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE

CREAM;TOPICAL
HYDROCORTISONE

AT		RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar	CAHN
>D>		POWDER;FOR RX COMPOUNDING						
>D>		HYDRO-RX						
>D>	+	X GEN PHARMS	100%	A085982	001		Apr	DISC
>A>	@		100%	A085982	001		Apr	DISC

TABLET;ORAL
HYDROCORTISONE

AB		HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb	NEWA
AB			10MG	A083365	003	Feb 23, 2015	Feb	NEWA
AB			20MG	A083365	001		Feb	CMFD

HYDROCORTISONE ACETATE

>D>		POWDER;FOR RX COMPOUNDING						
>D>		HYDROCORTISONE ACETATE						
>D>		X GEN PHARMS	100%	A085981	001		Apr	DISC
>A>	@		100%	A085981	001		Apr	DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL
HYDROCORTISONE VALERATE

>A>	@	G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr	CAHN
>D>	@	TEVA PHARMS	0.2%	A074489	001	Aug 12, 1998	Apr	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar	NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION
CYANOKIT

>D>	@	MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr	CAHN
>D>	+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	CAHN
>A>	@	SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr	CAHN
>A>	+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

	@	ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar	CAHN
	@		250MG/ML	N017439	002		Mar	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar	CMFD

HYDROXYZINE PAMOATE

	CAPSULE;ORAL						
	HYDROXYZINE PAMOATE						
AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

ILOPERIDONE

TABLET;ORAL
FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan	CAHN
		2MG	N022192	002	May 06, 2009	Jan	CAHN
		4MG	N022192	003	May 06, 2009	Jan	CAHN
		6MG	N022192	004	May 06, 2009	Jan	CAHN
		8MG	N022192	005	May 06, 2009	Jan	CAHN
		10MG	N022192	006	May 06, 2009	Jan	CAHN
		12MG	N022192	007	May 06, 2009	Jan	CAHN

IMIQUIMOD

CREAM;TOPICAL
IMIQUIMOD

>A>	AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr	CAHN
>D>	AB	TEVA PHARMS USA	5%	A200481	001	Apr 18, 2011	Apr	CAHN

INSULIN GLARGINE

SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N206538	001	Feb 25, 2015	Feb	NEWA
---	--------------------	---------------------------	---------	-----	--------------	-----	------

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N206538	001	Feb 25, 2015	Feb	NEWA
---	--------------------	---------------------------	---------	-----	--------------	-----	------

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION
AFREZZA

>A>		SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr	NEWA
-----	--	----------------	--------------	---------	-----	--------------	-----	------

IOHEXOL

FOR SOLUTION;ORAL
ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar	NEWA
--	----------------------	-----------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE;INJECTION
IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan	DISC
---	--------------------	-----	---------	-----	--------------	-----	------

@	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan	DISC
---	--------------------	-----	---------	-----	--------------	-----	------

@	FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan	DISC
---	--------------------	-----	---------	-----	--------------	-----	------

ISOVUE-200

+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb	CTEC
---	--------	-----	---------	-----	--------------	-----	------

ISOVUE-250

+	BRACCO	51%	N018735	007	Jul 06, 1992	Feb	CTEC
---	--------	-----	---------	-----	--------------	-----	------

+		51%	N020327	002	Oct 12, 1994	Feb	CTEC
---	--	-----	---------	-----	--------------	-----	------

ISOVUE-300

+	BRACCO	61%	N020327	003	Oct 12, 1994	Feb	CTEC
---	--------	-----	---------	-----	--------------	-----	------

ISOVUE-370

+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb	CTEC
---	--------	-----	---------	-----	--------------	-----	------

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION
CONRAY

+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb	CAHN
---	------------------	-----	---------	-----	--	-----	------

CONRAY 30

+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb	CAHN
---	------------------	-----	---------	-----	--	-----	------

CONRAY 43

+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb	CAHN
---	------------------	-----	---------	-----	--	-----	------

SOLUTION; INTRAVESICAL
CYSTO-CONRAY II

LIEBEL-FLARSHEIM 17.2% N017057 002 Feb CAHN

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

@ LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988 Feb CAHN

OPTIRAY 240

+ LIEBEL-FLARSHEIM 51% N019710 002 Dec 30, 1988 Feb CAHN

@ 51% N020923 001 May 28, 1998 Feb CAHN

OPTIRAY 300

+ LIEBEL-FLARSHEIM 64% N019710 004 Jan 22, 1992 Feb CAHN

+ 64% N020923 004 May 13, 1999 Feb CAHN

OPTIRAY 320

+ LIEBEL-FLARSHEIM 68% N019710 001 Dec 30, 1988 Feb CAHN

@ 68% N020923 002 May 29, 1998 Feb CAHN

OPTIRAY 350

+ LIEBEL-FLARSHEIM 74% N019710 005 Jan 22, 1992 Feb CAHN

+ 74% N020923 003 May 28, 1998 Feb CAHN

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB JUBILANT GENERICS 75MG A203534 001 Feb 23, 2015 Feb NEWA

AB 150MG A203534 002 Feb 23, 2015 Feb NEWA

AB 300MG A203534 003 Feb 23, 2015 Feb NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP + ACTAVIS LABS UT INC EQ 50MG IRON/ML N017441 001 Mar CAHN

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+ ASTELLAS 186MG N207500 001 Mar 06, 2015 Mar NEWA

POWDER; IV (INFUSION)

CRESEMBA

+ ASTELLAS 372MG N207501 001 Mar 06, 2015 Mar NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB VALEANT PHARMS NORTH 5MG N012093 007 Jul 29, 1988 Feb CAHN

@ 10MG N012093 002 Jul 29, 1988 Feb CAHN

@ 20MG N012093 006 Jul 29, 1988 Feb CAHN

@ 30MG N012093 005 Jul 29, 1988 Feb CAHN

+ 40MG N012093 001 Jul 29, 1988 Feb CAHN

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

RANBAXY

25MG N021951 005 Aug 15, 2014 Feb NEWA

35MG N021951 006 Aug 15, 2014 Feb NEWA

SOTRET

>D> AB RANBAXY 10MG A076041 001 Dec 24, 2002 Apr CAHN

>D> AB 20MG A076041 002 Dec 24, 2002 Apr CAHN

>D> AB 30MG A076503 001 Jun 20, 2003 Apr CAHN

>D> AB 40MG A076041 003 Dec 24, 2002 Apr CAHN

>A> AB SUN PHARM INDS LTD 10MG A076041 001 Dec 24, 2002 Apr CAHN

>A> AB 20MG A076041 002 Dec 24, 2002 Apr CAHN

>A> AB 30MG A076503 001 Jun 20, 2003 Apr CAHN

>A> AB 40MG A076041 003 Dec 24, 2002 Apr CAHN

ZENATANE

AB DR REDDYS LABS LTD 30MG A202099 004 Feb 23, 2015 Feb NEWA

ISRADIPINECAPSULE;ORAL
ISRADIPINE

AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar	CAHN
AB		5MG	A077169	002	Apr 24, 2006	Mar	CAHN

>A> IVABRADINE HYDROCHLORIDETABLET;ORAL
CORLANOR

>A>	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr	NEWA
>A>	+	EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr	NEWA

IVACAFTORGRANULE;ORAL
KALYDECO

	VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar	NEWA
	+	75MG/PACKET	N207925	002	Mar 17, 2015	Mar	NEWA

KETOROLAC TROMETHAMINEINJECTABLE;INJECTION
KETOROLAC TROMETHAMINE

>D>	AP	AGILA SPECLTS	15MG/ML	A078299	001	Jul 16, 2007	Apr	CAHN
>D>	AP		30MG/ML	A078299	002	Jul 16, 2007	Apr	CAHN
>D>	@	APOTEX INC	15MG/ML	A075631	002	Jun 29, 2001	Apr	CAHN
>D>	@		30MG/ML	A075631	001	Jun 29, 2001	Apr	CAHN
>A>	@	CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr	CAHN
>A>	@		30MG/ML	A075631	001	Jun 29, 2001	Apr	CAHN
>A>	AP	MYLAN PHARMS INC	15MG/ML	A078299	001	Jul 16, 2007	Apr	CAHN
>A>	AP		30MG/ML	A078299	002	Jul 16, 2007	Apr	CAHN

SPRAY, METERED;NASAL
SPRIX

	+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan	CAHN
--	---	---------------	---------------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDESOLUTION;IRRIGATION
OMIDRIA

	+	OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb	CPOT
--	---	--------	--	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDEINJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

>D>	@	APOTEX INC	5MG/ML	A076051	001	Jul 05, 2002	Apr	CAHN
>A>	@	CLARIS PHARMASERVICE	5MG/ML	A076051	001	Jul 05, 2002	Apr	CAHN

TABLET;ORAL
LABETALOL HYDROCHLORIDE

AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan	CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan	CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan	CMFD

LACTULOSESOLUTION;ORAL, RECTAL
LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar	NEWA
----	---------------	-----------	---------	-----	--------------	-----	------

LAMIVUDINE; RALTEGRAVIR POTASSIUMTABLET;ORAL
DUTREBIS

	+	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb	NEWA
--	---	-------------------	---------------------	---------	-----	--------------	-----	------

LAMIVUDINE; ZIDOVUDINETABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

>A>	AB	STRIDES ARCOLAB LTD	150MG;300MG	A079128	001	May 13, 2015	Apr	NEWA
-----	----	---------------------	-------------	---------	-----	--------------	-----	------

LAPATINIB DITOSYLATETABLET;ORAL
TYKERB

	+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar	CAHN
--	---	----------------------	---------------	---------	-----	--------------	-----	------

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb	NEWA
+		EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb	NEWA

LEVETIRACETAM

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

	SPARC	1GM	N204417	001	Mar 02, 2015	Mar	NEWA
		1.5GM	N204417	002	Mar 02, 2015	Mar	NEWA

LEVETIRACETAM

	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA
--	------------	-----	---------	-----	--------------	-----	------

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

>D>	AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr	DISC
>A>		@	200MG/ML	A075881	001	Mar 29, 2001	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb	NEWA
----	--	------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

>D>	AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	CAHN
>A>	AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	CAHN
			LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	AP	CLARIS LIFESCIENCES	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr	CAHN
>D>	AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr	CAHN
>D>	AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr	CAHN
>A>	AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr	CAHN
>A>	AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr	CAHN
>A>	AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr	CAHN

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

		SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb	NEWA
		SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb	NEWA
	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

		MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb	NEWA
--	--	--------------	------	---------	-----	--------------	-----	------

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

>D>	+	ROXANE	2MG	A074278	001	Mar 31, 2000	Apr	CAHN
>A>	+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr	CAHN

LIDOCAINE

PATCH;TOPICAL

LIDOCAINE

AB		ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN
----	--	---------------------	----	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

	@	EUROHLTH INTL SARL	1%	A080407	001		Mar	CAHN
--	---	--------------------	----	---------	-----	--	-----	------

	@		2%	A080407	002		Mar	CAHN
--	---	--	----	---------	-----	--	-----	------

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

	@	EUROHLTH INTL SARL	1%	A084625	001		Feb	CAHN
--	---	--------------------	----	---------	-----	--	-----	------

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ 2%

A 084625 002

Feb CAHN

JELLY; TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%

A 080429 001

Jan CAHN

LIDOCAINE HYDROCHLORIDE

>A> @ G AND W LABS INC 2%

A 081318 001 Apr 29, 1993

Apr CAHN

>D> @ TEVA PHARMS USA 2%

A 081318 001 Apr 29, 1993

Apr CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ACTAVIS LABS UT INC 2.5%; 2.5%

N 019941 001 Dec 30, 1992

Feb CAHN

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC 145MCG

N 202811 001 Aug 30, 2012

Mar CAHN

+ 290MCG

N 202811 002 Aug 30, 2012

Mar CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

>D> AB RANBAXY 2.5MG

A 075944 001 Jul 01, 2002

Apr CAHN

>D> AB 5MG

A 075944 002 Jul 01, 2002

Apr CAHN

>D> AB 10MG

A 075944 003 Jul 01, 2002

Apr CAHN

>D> AB 20MG

A 075944 004 Jul 01, 2002

Apr CAHN

>D> AB 30MG

A 075944 006 Feb 11, 2003

Apr CAHN

>D> AB 40MG

A 075944 005 Jul 01, 2002

Apr CAHN

>A> AB SUN PHARM INDS LTD 2.5MG

A 075944 001 Jul 01, 2002

Apr CAHN

>A> AB 5MG

A 075944 002 Jul 01, 2002

Apr CAHN

>A> AB 10MG

A 075944 003 Jul 01, 2002

Apr CAHN

>A> AB 20MG

A 075944 004 Jul 01, 2002

Apr CAHN

>A> AB 30MG

A 075944 006 Feb 11, 2003

Apr CAHN

>A> AB 40MG

A 075944 005 Jul 01, 2002

Apr CAHN

ZESTRIL

AB ALVOGEN IPCO SARL 2.5MG

N 019777 005 Apr 29, 1993

Feb CAHN

AB 5MG

N 019777 001 May 19, 1988

Feb CAHN

AB 10MG

N 019777 002 May 19, 1988

Feb CAHN

AB 20MG

N 019777 003 May 19, 1988

Feb CAHN

AB 30MG

N 019777 006 Jan 20, 1999

Feb CAHN

AB + 40MG

N 019777 004 May 19, 1988

Feb CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

@ HIKMA INTL PHARMS 450MG

A 076490 001 Jun 17, 2003

Feb DISC

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

>A> AEGERION EQ 30MG BASE

N 203858 004 Apr 23, 2015

Apr NEWA

>A> EQ 40MG BASE

N 203858 005 Apr 23, 2015

Apr NEWA

>A> EQ 60MG BASE

N 203858 006 Apr 23, 2015

Apr NEWA

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

CORDEN PHARMA 5MG

N 017588 004 Dec 19, 2014

Jan NEWA

LORAZEPAM

TABLET; ORAL

LORAZEPAM

>D> AB RANBAXY 0.5MG

A 076045 001 Aug 29, 2001

Apr CAHN

>D> AB 1MG

A 076045 002 Aug 29, 2001

Apr CAHN

>D> AB 2MG

A 076045 003 Aug 29, 2001

Apr CAHN

>A> AB SUN PHARM INDS LTD 0.5MG

A 076045 001 Aug 29, 2001

Apr CAHN

>A> AB 1MG

A 076045 002 Aug 29, 2001

Apr CAHN

>A> AB 2MG

A 076045 003 Aug 29, 2001

Apr CAHN

LOSARTAN POTASSIUM

TABLET; ORAL		LOSARTAN POTASSIUM					
AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb	CMFD
AB		50MG	A091129	002	Oct 06, 2010	Feb	CMFD
AB		100MG	A091129	003	Oct 06, 2010	Feb	CMFD

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL		LOXITANE C					
	@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar	CAHN
INJECTABLE; INJECTION		LOXITANE IM					
	@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar	CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL		LOXITANE					
	@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar	CAHN
	@	EQ 10MG BASE	N017525	002		Mar	CAHN
	@	EQ 25MG BASE	N017525	003		Mar	CAHN
	@	EQ 50MG BASE	N017525	004		Mar	CAHN
TABLET; ORAL		LOXITANE					
	@ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
	@	EQ 25MG BASE	N017525	007		Mar	CAHN
	@	EQ 50MG BASE	N017525	008		Mar	CAHN

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION		PLASMA-LYTE 56 IN PLASTIC CONTAINER					
	@ BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC

MAGNESIUM SULFATE

>D>		INJECTABLE; INJECTION						
>D>		MAGNESIUM SULFATE						
>D>	AP	EXELA PHARMA SCS LLC	500MG/ML	A206039	001	Dec 18, 2014	Apr	CDFR
>D>	AP	+ FRESENIUS KABI USA	500MG/ML	N019316	001	Sep 08, 1986	Apr	CPOT
>D>	AP	+ HOSPIRA	500MG/ML	A075151	001	Apr 25, 2000	Apr	CDFR
>A>		SOLUTION; INTRAMUSCULAR, INTRAVENOUS						
>A>		MAGNESIUM SULFATE						
>A>	AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr	CDFR
>A>	AP	+ FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr	CPOT
>A>	AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr	CDFR
>A>		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr	NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS		MAGNESIUM SULFATE						
>A>		+ FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr	NEWA

MANNITOL

INJECTABLE; INJECTION		MANNITOL 25%					
	@ IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
	@	12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		NAMENDA XR						
	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar	CAHN	
		14MG	N022525	002	Jun 21, 2010	Mar	CAHN	
		21MG	N022525	003	Jun 21, 2010	Mar	CAHN	
	+	28MG	N022525	004	Jun 21, 2010	Mar	CAHN	
SOLUTION; ORAL		NAMENDA						
	+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar	CAHN
TABLET; ORAL		MEMANTINE						
AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar	CMFD	

TABLET;ORAL
MEMANTINE

AB		10MG	A090058	002	May 05, 2010	Mar	CMFD
	MEMANTINE HYDROCHLORIDE						
AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar	NEWA
AB		10MG	A090041	002	Apr 10, 2015	Mar	NEWA
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar	NEWA
AB	@ MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Mar	DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan	NEWA
AB	@	10MG	A079225	002	Jan 30, 2015	Mar	DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan	NEWA
	NAMENDA						
AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Mar	CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb	CAHN
AP		50MG/ML	A080445	002		Feb	CAHN
AP		75MG/ML	A080445	003		Feb	CAHN
AP		100MG/ML	A080445	004		Feb	CAHN
	@ IGI LABS INC	50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN
	@	50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN
	@	50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN
	@	75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN

MEROPENEM

>A>	POWDER; IV (INFUSION)						
>A>	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER						
>A>	B BRAUN MEDICAL INC	1GM/VIAL	N202106	002	Apr 30, 2015	Apr	NEWA
>A>		500MG/VIAL	N202106	001	Apr 30, 2015	Apr	NEWA

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20
NORINYL

	@ ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004		Mar	CAHN
	TABLET;ORAL-21 NORINYL 1+50 21-DAY						
	@ ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002		Mar	CAHN
	TABLET;ORAL-28 NORINYL 1+50 28-DAY						
	+ ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Mar	CAHN

METAPROTERENOL SULFATE

>D>	SOLUTION; INHALATION						
>D>	METAPROTERENOL SULFATE						
>D>	AN + MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr	DISC
>A>	@	0.4%	A071786	001	Aug 05, 1988	Apr	DISC
>D>	AN +	0.6%	A070804	001	Aug 17, 1987	Apr	DISC
>A>	@	0.6%	A070804	001	Aug 17, 1987	Apr	DISC
>D>	AN WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr	DISC
>A>	@	0.4%	A075586	001	May 30, 2002	Apr	DISC
>D>	AN	0.6%	A075586	002	May 30, 2002	Apr	DISC
>A>	@	0.6%	A075586	002	May 30, 2002	Apr	DISC
	SYRUP;ORAL						
	METAPROTERENOL SULFATE						
>A>	@ G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr	CAHN
>A>	@	10MG/5ML	A073034	001	Aug 30, 1991	Apr	CAHN
>D>	@ TEVA	10MG/5ML	A072761	001	Feb 27, 1992	Apr	CAHN
>D>	@ TEVA PHARMS	10MG/5ML	A073034	001	Aug 30, 1991	Apr	CAHN

METAXALONE

TABLET;ORAL
METAXALONE

	COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb	NEWA
--	------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

RIOMET

>D>	+	RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Apr CAHN
>A>	+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr CAHN

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB			10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

APTENSIO XR

>A>		RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr NEWA
>A>			15MG	N205831	002	Apr 17, 2015	Apr NEWA
>A>			20MG	N205831	003	Apr 17, 2015	Apr NEWA
>A>			30MG	N205831	004	Apr 17, 2015	Apr NEWA
>A>			40MG	N205831	005	Apr 17, 2015	Apr NEWA
>A>			50MG	N205831	006	Apr 17, 2015	Apr NEWA
>A>	+		60MG	N205831	007	Apr 17, 2015	Apr NEWA
		RITALIN LA					
AB1		NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb CRLD
	+		60MG	N021284	005	Oct 27, 2014	Feb CRLD

TABLET, CHEWABLE;ORAL

METHYLIN

AB		MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb CFTG
AB			5MG	N021475	002	Apr 15, 2003	Feb CFTG
AB	+		10MG	N021475	003	Apr 15, 2003	Feb CFTG
		METHYLPHENIDATE HYDROCHLORIDE					
AB		NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb NEWA
AB			5MG	A204115	002	Feb 25, 2015	Feb NEWA
AB			10MG	A204115	003	Feb 25, 2015	Feb NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

>D>	AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN
>A>	AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN

TABLET;ORAL

METOPROLOL TARTRATE

		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar NEWA
			75MG	A076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLE

CREAM;TOPICAL

NORITATE

	+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb CAHN
--	---	----------------------	----	---------	-----	--------------	----------

GEL;VAGINAL

METRONIDAZOLE

	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CAHN
--	---	---------------------	------	---------	-----	--------------	----------

NUVESSA

	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CTNA
--	---	---------------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

>D>	AP	CLARIS LIFESCIENCES	500MG/100ML	A078084	001	Mar 31, 2008	Apr CAHN
>A>	AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr CAHN

MICONAZOLE

TABLET;BUCCAL

ORAVIG

>D>	+	BIOALLIANCE PHARMA	50MG	N022404	001	Apr 16, 2010	Apr CAHN
>A>	+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	@	APOTEX INC	EQ 1MG BASE/ML	A 075637	001	Oct 31, 2000	Apr	CAHN
>D>	@		EQ 5MG BASE/ML	A 075637	002	Oct 31, 2000	Apr	CAHN
>D>	@	ASTRAZENECA	EQ 5MG BASE/ML	A 075263	001	Jun 26, 2000	Apr	CAHN
>A>	@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A 075637	001	Oct 31, 2000	Apr	CAHN
>A>	@		EQ 5MG BASE/ML	A 075637	002	Oct 31, 2000	Apr	CAHN
>A>	@	IGI LABS INC	EQ 5MG BASE/ML	A 075263	001	Jun 26, 2000	Apr	CAHN
	@	WOCKHARDT	EQ 1MG BASE/ML	A 078141	001	May 30, 2008	Mar	DISC
	@		EQ 1MG BASE/ML	A 078511	001	Nov 10, 2008	Mar	DISC
	@		EQ 5MG BASE/ML	A 078141	002	May 30, 2008	Mar	DISC
	@		EQ 5MG BASE/ML	A 078511	002	Nov 10, 2008	Mar	DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

>D>	AA	RANBAXY	EQ 2MG BASE/ML	A 076058	001	Mar 15, 2002	Apr	CAHN
>A>	AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A 076058	001	Mar 15, 2002	Apr	CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB		PHARMACIA AND UPJOHN	25MG	N 020682	001	Dec 18, 1996	Mar	CTEC
AA			25MG	N 020682	001	Dec 18, 1996	Feb	CFTG
AB			50MG	N 020682	002	Dec 18, 1996	Mar	CTEC
AA			50MG	N 020682	002	Dec 18, 1996	Feb	CFTG
AB	+		100MG	N 020682	003	Dec 18, 1996	Mar	CTEC
AA	+		100MG	N 020682	003	Dec 18, 1996	Feb	CFTG

MIGLITOL

AB		ORIENT PHARMA CO LTD	25MG	A 203965	001	Feb 24, 2015	Mar	CTEC
AA			25MG	A 203965	001	Feb 24, 2015	Feb	NEWA
AB			50MG	A 203965	002	Feb 24, 2015	Mar	CTEC
AA			50MG	A 203965	002	Feb 24, 2015	Feb	NEWA
AB			100MG	A 203965	003	Feb 24, 2015	Mar	CTEC
AA			100MG	A 203965	003	Feb 24, 2015	Feb	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP		BEDFORD	EQ 1MG BASE/ML	A 075660	001	May 28, 2002	Jan	CRLD
AP	+	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A 077966	001	Dec 03, 2010	Jan	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	RANBAXY	EQ 50MG BASE	A 065062	001	Nov 30, 2000	Apr	CAHN
>D>	AB		EQ 75MG BASE	A 065062	002	Nov 30, 2000	Apr	CAHN
>D>	AB		EQ 100MG BASE	A 065062	003	Nov 30, 2000	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 50MG BASE	A 065062	001	Nov 30, 2000	Apr	CAHN
>A>	AB		EQ 75MG BASE	A 065062	002	Nov 30, 2000	Apr	CAHN
>A>	AB		EQ 100MG BASE	A 065062	003	Nov 30, 2000	Apr	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

>D>	@	RANBAXY LABS LTD	EQ 45MG BASE	N 201922	001	Jul 11, 2012	Apr	CAHN
>D>	@		EQ 67.5MG BASE	N 201922	002	Jul 11, 2012	Apr	CAHN
>D>	@		EQ 90MG BASE	N 201922	003	Jul 11, 2012	Apr	CAHN
>D>	@		EQ 112.5MG BASE	N 201922	004	Jul 11, 2012	Apr	CAHN
>D>	@		EQ 135MG BASE	N 201922	005	Jul 11, 2012	Apr	CAHN
>A>	@	SUN PHARM INDS LTD	EQ 45MG BASE	N 201922	001	Jul 11, 2012	Apr	CAHN
>A>	@		EQ 67.5MG BASE	N 201922	002	Jul 11, 2012	Apr	CAHN
>A>	@		EQ 90MG BASE	N 201922	003	Jul 11, 2012	Apr	CAHN
>A>	@		EQ 112.5MG BASE	N 201922	004	Jul 11, 2012	Apr	CAHN
>A>	@		EQ 135MG BASE	N 201922	005	Jul 11, 2012	Apr	CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	RANBAXY	EQ 50MG BASE	A 065156	001	Jan 06, 2004	Apr	CAHN
>D>	AB		EQ 75MG BASE	A 065156	002	Jan 06, 2004	Apr	CAHN
>D>	AB		EQ 100MG BASE	A 065156	003	Jan 06, 2004	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 50MG BASE	A 065156	001	Jan 06, 2004	Apr	CAHN
>A>	AB		EQ 75MG BASE	A 065156	002	Jan 06, 2004	Apr	CAHN
>A>	AB		EQ 100MG BASE	A 065156	003	Jan 06, 2004	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

>D>	AB	RANBAXY LABS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
>D>	AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
>D>	AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN
>D>	AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
>D>	AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
>A>	AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
>A>	AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN
>A>	AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
>A>	AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS
MIVACRON

		ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
+			EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET;ORAL
MOLINDONE HYDROCHLORIDE

		COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
			10MG	A090453	002	Mar 20, 2015	Mar NEWA
+			25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

TABLET;ORAL
MONTELUKAST SODIUM

AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN
AB		JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
AB			EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
AB		KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
AB			EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
AB			EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN
			130MG	N020616	011	Jul 09, 2012	Mar CAHN
			150MG	N020616	012	Jul 09, 2012	Mar CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA
AB			100MG	A203849	004	Apr 06, 2015	Mar NEWA
AB			200MG	A203849	005	Apr 06, 2015	Mar NEWA
>D>	AB	RANBAXY LABS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
>D>	AB		30MG	A078761	002	May 11, 2012	Apr CAHN
>D>	AB		60MG	A078761	003	May 11, 2012	Apr CAHN
>D>	AB		100MG	A078761	004	May 11, 2012	Apr CAHN
>D>	AB		200MG	A078761	005	May 11, 2012	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
>A>	AB		30MG	A078761	002	May 11, 2012	Apr CAHN
>A>	AB		60MG	A078761	003	May 11, 2012	Apr CAHN
>A>	AB		100MG	A078761	004	May 11, 2012	Apr CAHN
>A>	AB		200MG	A078761	005	May 11, 2012	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

>A> SOLUTION;IV (INFUSION)
 >A> MOXIFLOXACIN HYDROCHLORIDE
 >A> + FRESENIUS KABI USA EQ 400MG BASE/250ML (EQ 1.6MG N205572 001 Apr 03, 2015 Apr NEWA
 BASE/ML)
 SOLUTION/DROPS;OPHTHALMIC
 MOXIFLOXACIN HYDROCHLORIDE
 AT WATSON LABS INC EQ 0.5% BASE A202525 001 Mar 06, 2015 Feb NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION
 NALBUPHINE HYDROCHLORIDE
 @ IGI LABS INC 10MG/ML A072070 001 Apr 10, 1989 Mar CAHN
 @ 10MG/ML A072071 001 Apr 10, 1989 Mar CAHN
 @ 10MG/ML A072072 001 Apr 10, 1989 Mar CAHN
 @ 20MG/ML A072073 001 Apr 10, 1989 Mar CAHN
 @ 20MG/ML A072074 001 Apr 10, 1989 Mar CAHN
 @ 20MG/ML A072075 001 Apr 10, 1989 Mar CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
 NALOXONE
 @ EUROHLTH INTL SARL 0.4MG/ML A070299 001 Sep 24, 1986 Mar CAHN
 NALOXONE HYDROCHLORIDE
 @ IGI LABS INC 0.02MG/ML A072082 001 Apr 11, 1989 Mar CAHN
 @ 0.02MG/ML A072083 001 Apr 11, 1989 Mar CAHN
 @ 0.02MG/ML A072084 001 Apr 11, 1989 Mar CAHN
 @ 0.02MG/ML A072085 001 Apr 11, 1989 Mar CAHN
 @ 0.4MG/ML A072086 001 Apr 11, 1989 Mar CAHN
 @ 0.4MG/ML A072087 001 Apr 11, 1989 Mar CAHN
 @ 0.4MG/ML A072088 001 Apr 11, 1989 Mar CAHN
 @ 0.4MG/ML A072089 001 Apr 11, 1989 Mar CAHN
 @ 0.4MG/ML A072090 001 Apr 11, 1989 Mar CAHN
 @ 1MG/ML A072091 001 Apr 11, 1989 Mar CAHN
 @ 1MG/ML A072092 001 Apr 11, 1989 Mar CAHN
 @ 1MG/ML A072093 001 Apr 11, 1989 Mar CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
 >D> AB RANBAXY EQ 0.5MG BASE;EQ 50MG BASE A075523 001 Mar 17, 2000 Apr CAHN
 >A> AB SUN PHARM INDS LTD EQ 0.5MG BASE;EQ 50MG BASE A075523 001 Mar 17, 2000 Apr CAHN

NAPROXEN

SUSPENSION;ORAL
 NAPROSYN
 >A> AB + PEDIAPHARM INC 25MG/ML N018965 001 Mar 23, 1987 Apr CAHN
 >D> AB + ROCHE PALO 25MG/ML N018965 001 Mar 23, 1987 Apr CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL
 BYSTOLIC
 >D> AB FOREST LABS EQ 2.5MG BASE N021742 002 Dec 17, 2007 Apr CTEC
 >A> EQ 2.5MG BASE N021742 002 Dec 17, 2007 Apr CTEC
 AB EQ 2.5MG BASE N021742 002 Dec 17, 2007 Mar CFTG
 >D> AB EQ 5MG BASE N021742 003 Dec 17, 2007 Apr CTEC
 >A> EQ 5MG BASE N021742 003 Dec 17, 2007 Apr CTEC
 AB EQ 5MG BASE N021742 003 Dec 17, 2007 Mar CFTG
 >D> AB EQ 10MG BASE N021742 004 Dec 17, 2007 Apr CTEC
 >A> EQ 10MG BASE N021742 004 Dec 17, 2007 Apr CTEC
 AB EQ 10MG BASE N021742 004 Dec 17, 2007 Mar CFTG
 >D> AB + EQ 20MG BASE N021742 005 Oct 08, 2008 Apr CTEC
 >A> + EQ 20MG BASE N021742 005 Oct 08, 2008 Apr CTEC
 AB + EQ 20MG BASE N021742 005 Oct 08, 2008 Mar CFTG
 >D> NEBIVOLOL HYDROCHLORIDE
 >D> AB AMERIGEN PHARMS LTD EQ 2.5MG BASE A203659 001 Apr 16, 2015 Apr DISC
 >A> @ EQ 2.5MG BASE A203659 001 Apr 16, 2015 Apr DISC
 AB EQ 2.5MG BASE A203659 001 Apr 16, 2015 Mar NEWA
 >D> AB EQ 5MG BASE A203659 002 Apr 16, 2015 Apr DISC
 >A> @ EQ 5MG BASE A203659 002 Apr 16, 2015 Apr DISC
 AB EQ 5MG BASE A203659 002 Apr 16, 2015 Mar NEWA
 >D> AB EQ 10MG BASE A203659 003 Apr 16, 2015 Apr DISC

TABLET;ORALNEBIVOLOL HYDROCHLORIDE

>A>	@	EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr	DISC
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar	NEWA
>D>	AB	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr	DISC
>A>	@	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr	DISC
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar	NEWA

NEFAZODONE HYDROCHLORIDETABLET;ORALNEFAZODONE HYDROCHLORIDE

>A>	@	IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr	CAHN
>A>	@		100MG	A076072	002	Sep 16, 2003	Apr	CAHN
>A>	@		150MG	A076072	003	Sep 16, 2003	Apr	CAHN
>A>	@		200MG	A076072	004	Sep 16, 2003	Apr	CAHN
>A>	@		250MG	A076072	005	Sep 16, 2003	Apr	CAHN
>D>	AB	RANBAXY	50MG	A076409	001	Sep 16, 2003	Apr	CAHN
>D>	AB		100MG	A076409	002	Sep 16, 2003	Apr	CAHN
>D>	AB		150MG	A076409	003	Sep 16, 2003	Apr	CAHN
>D>	AB		200MG	A076409	004	Sep 16, 2003	Apr	CAHN
>D>	AB		250MG	A076409	005	Sep 16, 2003	Apr	CAHN
>D>	@	SANDOZ	50MG	A076072	001	Sep 16, 2003	Apr	CAHN
>D>	@		100MG	A076072	002	Sep 16, 2003	Apr	CAHN
>D>	@		150MG	A076072	003	Sep 16, 2003	Apr	CAHN
>D>	@		200MG	A076072	004	Sep 16, 2003	Apr	CAHN
>D>	@		250MG	A076072	005	Sep 16, 2003	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr	CAHN
>A>	AB		100MG	A076409	002	Sep 16, 2003	Apr	CAHN
>A>	AB		150MG	A076409	003	Sep 16, 2003	Apr	CAHN
>A>	AB		200MG	A076409	004	Sep 16, 2003	Apr	CAHN
>A>	AB		250MG	A076409	005	Sep 16, 2003	Apr	CAHN

NELARABINEINJECTABLE;IV (INFUSION)ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN
---	----------------------	---------------------	---------	-----	--------------	-----	------

NEOSTIGMINE METHYLSULFATESOLUTION;INTRAVENOUSNEOSTIGMINE METHYLSULFATE

	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan	NEWA
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan	NEWA

NIFEDIPINECAPSULE;ORALNIFEDIPINE

AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN
AB		20MG	A202644	002	Apr 25, 2013	Mar	CAHN

NILUTAMIDETABLET;ORALNILANDRON

>A>	@	CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
>A>	+		150MG	N020169	002	Apr 30, 1999	Apr	CAHN
>D>	@	COVIS PHARMA SARL	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
>D>	+		150MG	N020169	002	Apr 30, 1999	Apr	CAHN

NIMODIPINECAPSULE;ORALNIMODIPINE

AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
----	---	----------------------	------	---------	-----	--------------	-----	------

NINTEDANIB ESYLATECAPSULE;ORALOFEV

	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CAIN
+		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CAIN

NORETHINDRONE

TABLET; ORAL-28
NOR-QD

AB1 + ACTAVIS LABS UT INC 0.35MG N017060 001 Mar CAHN

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

>D> AA ACTAVIS MID ATLANTIC 100,000 UNITS/ML A062349 001 Jul 14, 1982 Apr CAHN
>A> AA G AND W LABS INC 100,000 UNITS/ML A062349 001 Jul 14, 1982 Apr CAHN
>A> @ 100,000 UNITS/ML A062776 001 Dec 17, 1987 Apr CAHN
>D> @ TEVA 100,000 UNITS/ML A062776 001 Dec 17, 1987 Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM; 0.1% A062367 001 May 28, 1985 Mar CMFD

OINTMENT; TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM; 0.1% A062733 001 Mar 09, 1987 Mar CMFD

OLANZAPINE

TABLET; ORAL
OLANZAPINE

>A> AB IVAX PHARMS INC 20MG A077301 001 Apr 29, 2015 Apr NEWA
TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE
AB MACLEODS PHARMS LTD 5MG A203044 001 Feb 20, 2015 Feb NEWA
AB 10MG A203044 002 Feb 20, 2015 Feb NEWA
AB 15MG A203044 003 Feb 20, 2015 Feb NEWA
AB 20MG A203044 004 Feb 20, 2015 Feb NEWA
AB ORCHID HLTHCARE 5MG A202937 001 Mar 02, 2015 Feb NEWA
AB 10MG A202937 002 Mar 02, 2015 Feb NEWA
AB 15MG A202937 003 Mar 02, 2015 Feb NEWA
AB 20MG A202937 004 Mar 02, 2015 Feb NEWA

OLAPARIB

CAPSULE; ORAL
LYNPARZA

ASTRAZENECA PHARMS 50MG N206162 001 Dec 19, 2014 Jan CTNA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
PAZEO

+ ALCON RES LTD EQ 0.7% BASE N206276 001 Jan 30, 2015 Jan NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

>D> AB RANBAXY 4MG A078602 001 Feb 24, 2011 Apr CAHN
>D> AB 8MG A078602 002 Feb 24, 2011 Apr CAHN
>A> AB SUN PHARM INDS LTD 4MG A078602 001 Feb 24, 2011 Apr CAHN
>A> AB 8MG A078602 002 Feb 24, 2011 Apr CAHN
ZOFTRAN ODT
AB NOVARTIS PHARMS CORP 4MG N020781 001 Jan 27, 1999 Mar CAHN
AB + 8MG N020781 002 Jan 27, 1999 Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

>D> AP CLARIS LIFESCIENCES EQ 2MG BASE/ML A078288 001 Feb 22, 2013 Apr CAHN
>A> AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A078288 001 Feb 22, 2013 Apr CAHN
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER
>D> @ CLARIS LIFESCIENCES EQ 0.64MG BASE/ML A078308 001 Mar 17, 2008 Apr CAHN
>A> @ CLARIS PHARMASERVICE EQ 0.64MG BASE/ML A078308 001 Mar 17, 2008 Apr CAHN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
>D> AP AGILA SPECLTS EQ 2MG BASE/ML A078244 001 Apr 23, 2008 Apr CAHN
>D> AP CLARIS LIFESCIENCES EQ 2MG BASE/ML A078287 001 Feb 22, 2013 Apr CAHN
>A> AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A078287 001 Feb 22, 2013 Apr CAHN
>A> AP MYLAN PHARMS INC EQ 2MG BASE/ML A078244 001 Apr 23, 2008 Apr CAHN
@ TARO PHARMS IRELAND EQ 2MG BASE/ML A078014 001 Mar 21, 2008 Jan DISC

INJECTABLE; INJECTION

Code	Manufacturer	Strength	NDA	Approval	Effective	Expiration	Agency
AP	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CAHN
ZOFRAN							
AP	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CAHN
SOLUTION; ORAL							
ZOFRAN							
AA	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar	CAHN
TABLET; ORAL							
ZOFRAN							
AB	NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar	CAHN
AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar	CAHN
AB		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar	CAHN

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

Code	Manufacturer	Strength	NDA	Approval	Effective	Expiration	Agency
>A>	IGI LABS INC	30MG/ML	N013055	001		Apr	CAHN
>D>	MEDICIS	30MG/ML	N013055	001		Apr	CAHN
>D>		30MG/ML	N013055	001		Mar	DISC
ORPHENADRINE CITRATE							
AP	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar	CRLD

OXCARBAZEPINE

SUSPENSION; ORAL

Code	Manufacturer	Strength	NDA	Approval	Effective	Expiration	Agency
>D>	RANBAXY	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN
>A>	SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

Code	Manufacturer	Strength	NDA	Approval	Effective	Expiration	Agency
AB	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar	CAHN
OXYTROL							
GEL, METERED; TRANSDERMAL							
GELNIQUE 3%							
	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar	CAHN

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

Code	Manufacturer	Strength	NDA	Approval	Effective	Expiration	Agency
	ACTAVIS LABS UT INC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Mar	CAHN

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

Code	Manufacturer	Strength	NDA	Approval	Effective	Expiration	Agency
>A>	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr	NEWA
OXYCODONE HYDROCHLORIDE							
TABLET; ORAL							
OXAYDO							
	ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar	CTNA
		7.5MG	N202080	002	Jun 17, 2011	Mar	CTNA
OXYCODONE HYDROCHLORIDE							
AB	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar	NEWA
AB	VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar	NEWA
AB		20MG	A077712	005	Apr 13, 2015	Mar	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

Code	Manufacturer	Strength	NDA	Approval	Effective	Expiration	Agency
>A>	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr	NEWA
>A>		7.5MG	A203506	002	Apr 24, 2015	Apr	NEWA
>A>		10MG	A203506	003	Apr 24, 2015	Apr	NEWA
>A>		15MG	A203506	004	Apr 24, 2015	Apr	NEWA
>A>		20MG	A203506	005	Apr 24, 2015	Apr	NEWA
>A>		30MG	A203506	006	Apr 24, 2015	Apr	NEWA
>A>		40MG	A203506	007	Apr 24, 2015	Apr	NEWA

OXYTOCININJECTABLE; INJECTION
OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

>A>	AP	MYLAN PHARMS INC	6MG/ML	A091540	001	Sep 29, 2011	Apr	CAHN
>D>	AP	ONCO THERAPIES LTD	6MG/ML	A091540	001	Sep 29, 2011	Apr	CAHN

PALBOCICLIBCAPSULE; ORAL
IBRANCE

PFIZER INC

+

75MG

100MG

125MG

N207103 001 Feb 03, 2015 Feb NEWA

N207103 002 Feb 03, 2015 Feb NEWA

N207103 003 Feb 03, 2015 Feb NEWA

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

>D>	AP	AGILA SPECLTS	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Apr	CAHN
>D>	AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Apr	CAHN
>A>	AP	MYLAN PHARMS INC	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Apr	CAHN
>A>	AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Apr	CAHN

PANCURONIUM BROMIDEINJECTABLE; INJECTION
PANCURONIUM BROMIDE

@ IGI LABS INC

@

@

@

1MG/ML

2MG/ML

2MG/ML

2MG/ML

A072210 001 Mar 31, 1988 Mar CAHN

A072211 001 Mar 31, 1988 Mar CAHN

A072212 001 Mar 31, 1988 Mar CAHN

A072213 001 Mar 31, 1988 Mar CAHN

PANOBINOSTATCAPSULE; ORAL
FARYDAK

NOVARTIS PHARMS CORP

+

10MG

15MG

20MG

N205353 001 Feb 23, 2015 Feb NEWA

N205353 002 Feb 23, 2015 Feb NEWA

N205353 003 Feb 23, 2015 Feb NEWA

PANOBINOSTAT LACTATECAPSULE; ORAL
FARYDAK

NOVARTIS PHARMS CORP

+

+

EQ 10MG BASE

EQ 10MG BASE

EQ 15MG BASE

EQ 15MG BASE

EQ 20MG BASE

EQ 20MG BASE

N205353 001 Feb 23, 2015 Mar CAIN

N205353 001 Feb 23, 2015 Mar CPOT

N205353 002 Feb 23, 2015 Mar CAIN

N205353 002 Feb 23, 2015 Mar CPOT

N205353 003 Feb 23, 2015 Mar CAIN

N205353 003 Feb 23, 2015 Mar CPOT

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

KREMERS URBAN PHARMS

RANBAXY LABS LTD

SUN PHARM INDS LTD

>D>

>D>

>A>

>A>

EQ 20MG BASE

EQ 40MG BASE

EQ 20MG BASE

EQ 40MG BASE

EQ 20MG BASE

EQ 40MG BASE

A078281 001 Jan 20, 2011 Mar CAHN

A078281 002 Jan 20, 2011 Mar CAHN

A200794 001 May 02, 2012 Apr CAHN

A200794 002 May 02, 2012 Apr CAHN

A200794 001 May 02, 2012 Apr CAHN

A200794 002 May 02, 2012 Apr CAHN

PARICALCITOLCAPSULE; ORAL
PARICALCITOL

BANNER LIFE SCIENCES

AB

AB

AB

1MCG

2MCG

4MCG

A202539 001 Mar 27, 2014 Jan CAHN

A202539 002 Mar 27, 2014 Jan CAHN

A202539 003 Mar 27, 2014 Jan CAHN

PAZOPANIB HYDROCHLORIDETABLET; ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar	CAHN

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

PHENDIMETRAZINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
BONTRIL

	@ VALEANT	105MG	A088021	001	Sep 21, 1982	Jan	DISC
	PHENDIMETRAZINE TARTRATE						
+	SANDOZ	105MG	N018074	001		Jan	CTEC

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	NEWA
		10%	N207926	002	Jan 15, 2015	Jan	NEWA

PHENYTOIN SODIUMINJECTABLE; INJECTION
PHENYTOIN SODIUM

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb	CAHN
----	---	--------------------	---------	---------	-----	--	-----	------

PHYTONADIONEINJECTABLE; INJECTION
AQUAMEPHYTON

>D>	@	BIOVAIL TECHNOLOGIES	1MG/0.5ML	N012223	002		Apr	CAHN
>D>	@		10MG/ML	N012223	001		Apr	CAHN
>A>	@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr	CAHN
>A>	@		10MG/ML	N012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDETABLET; ORAL
PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar	CAHN
----	--	----------------------	-----	---------	-----	--------------	-----	------

PINDOLOLTABLET; ORAL
PINDOLOL

>A>	@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr	CAHN
>A>	@		5MG	A073687	001	Feb 26, 1993	Apr	CAHN
>A>	@		5MG	A074123	001	Apr 17, 1997	Apr	CAHN
>A>	@		10MG	A073661	002	Oct 31, 1993	Apr	CAHN
>A>	@		10MG	A073687	002	Feb 26, 1993	Apr	CAHN
>A>	@		10MG	A074123	002	Apr 17, 1997	Apr	CAHN
>D>	@	IVAX SUB TEVA PHARMS	5MG	A073687	001	Feb 26, 1993	Apr	CAHN
>D>	@		10MG	A073687	002	Feb 26, 1993	Apr	CAHN
>D>	@	TEVA	5MG	A073661	001	Oct 31, 1993	Apr	CAHN
>D>	@		5MG	A074123	001	Apr 17, 1997	Apr	CAHN
>D>	@		10MG	A073661	002	Oct 31, 1993	Apr	CAHN
>D>	@		10MG	A074123	002	Apr 17, 1997	Apr	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		AGILA SPECLTS	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar	CPOT
----	--	---------------	---	---------	-----	--------------	-----	------

PIRBUTEROL ACETATEAEROSOL, METERED; INHALATION
MAXAIR

	@	MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Jan	DISC
--	---	---------	-------------------	---------	-----	--------------	-----	------

PIRFENIDONECAPSULE;ORAL
ESBRIET

+ GENENTECH INC 267MG N022535 001 Oct 15, 2014 Feb CAHN

PODOFLOXGEL;TOPICAL
CONDYLOX

+ ACTAVIS LABS UT INC 0.5% N020529 001 Mar 13, 1997 Feb CAHN

SOLUTION;TOPICAL
CONDYLOX

AT + ACTAVIS LABS UT INC 0.5% N019795 001 Dec 13, 1990 Jan CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE

AA STRIDES ARCOLAB LTD 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A204559 001 Apr 13, 2015 Mar NEWA
.2GM/BOTPOLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT ALCON RES LTD 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

>A> ARIAD EQ 30MG BASE N203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB2 MYLAN PHARMS INC 8MEQ A204662 001 Aug 21, 2014 Feb CPOT

AB2 10MEQ A204662 002 Aug 21, 2014 Feb CPOT

PREDNICARBATE

OINTMENT;TOPICAL

DERMATOP

>D> AB + VALEANT BERMUDA 0.1% N019568 001 Sep 23, 1991 Apr CAHN

>A> AB + VALEANT PHARMS NORTH 0.1% N019568 001 Sep 23, 1991 Apr CAHN

PREGABALIN

CAPSULE;ORAL

LYRICA

>D> AB PF PRISM CV 25MG N021446 001 Dec 30, 2004 Apr CTEC

>A> 25MG N021446 001 Dec 30, 2004 Apr CTEC

>D> AB 50MG N021446 002 Dec 30, 2004 Apr CTEC

>A> 50MG N021446 002 Dec 30, 2004 Apr CTEC

>D> AB 75MG N021446 003 Dec 30, 2004 Apr CTEC

>A> 75MG N021446 003 Dec 30, 2004 Apr CTEC

>D> AB 100MG N021446 004 Dec 30, 2004 Apr CTEC

>A> 100MG N021446 004 Dec 30, 2004 Apr CTEC

>D> AB 150MG N021446 005 Dec 30, 2004 Apr CTEC

>A> 150MG N021446 005 Dec 30, 2004 Apr CTEC

>D> AB 200MG N021446 006 Dec 30, 2004 Apr CTEC

>A> 200MG N021446 006 Dec 30, 2004 Apr CTEC

>D> AB 225MG N021446 007 Dec 30, 2004 Apr CTEC

>A> 225MG N021446 007 Dec 30, 2004 Apr CTEC

>D> AB + 300MG N021446 008 Dec 30, 2004 Apr CTEC

>A> + 300MG N021446 008 Dec 30, 2004 Apr CTEC

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP + EUROHLTH INTL SARL EQ 5MG BASE/ML A089903 001 Aug 29, 1989 Feb CAHN

PROGESTERONE

CAPSULE; ORAL		PROGESTERONE					
AB	BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan	CAHN
GEL; VAGINAL		CRINONE					
	ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN
	+	8%	N020701	002	Jul 31, 1997	Feb	CAHN
INJECTABLE; INJECTION		PROGESTERONE					
AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL		PHENERGAN					
>A>	@ DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN
>A>	@	25MG	N010926	001		Apr	CAHN
>D>	@ SHIONOGI INC	12.5MG	N010926	002		Apr	CAHN
>D>	@	25MG	N010926	001		Apr	CAHN
TABLET; ORAL		PROMETHAZINE HYDROCHLORIDE					
AB	HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
AB		25MG	A040673	002	Mar 05, 2008	Mar	CAHN
AB		50MG	A040673	003	Mar 05, 2008	Mar	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL		QUINAPRIL HYDROCHLORIDE					
>D>	AB	RANBAXY	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
>D>	AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
>D>	AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
>D>	AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
>A>	AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
>A>	AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
>A>	AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL		QUINIDINE SULFATE					
>A>	+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN
>D>	+	TEVA PHARMS	300MG	A040045	001	Jun 30, 1994	Apr CAHN

QUININE SULFATE

CAPSULE; ORAL		QUININE SULFATE					
>A>	AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL		RALOXIFENE HYDROCHLORIDE					
AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL		RANITIDINE HYDROCHLORIDE					
>D>	@ RANBAXY	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr	CAHN
>D>	@	EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr	CAHN
>A>	@ SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr	CAHN
>A>	@	EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr	CAHN

REPAGLINIDE

TABLET; ORAL		REPAGLINIDE					
>A>	AB	STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA
>A>	AB		1MG	A091517	002	Apr 24, 2015	Apr NEWA
>A>	AB		2MG	A091517	003	Apr 24, 2015	Apr NEWA

RIFAMPININJECTABLE; INJECTION
RIFAMPIN

>D>	AP	AGILA SPECLTS	600MG/VIAL	A 065421	001	May 22, 2008	Apr	CAHN
>A>	AP	MYLAN PHARMS INC	600MG/VIAL	A 065421	001	May 22, 2008	Apr	CAHN

RISPERIDONETABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

>D>	AB	RANBAXY	0.5MG	A 077542	001	Aug 06, 2010	Apr	CAHN
>D>	AB		1MG	A 077542	002	Aug 06, 2010	Apr	CAHN
>D>	AB		2MG	A 077542	003	Aug 06, 2010	Apr	CAHN
>D>	AB		3MG	A 078474	001	Aug 06, 2010	Apr	CAHN
>D>	AB		4MG	A 078474	002	Aug 06, 2010	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	0.5MG	A 077542	001	Aug 06, 2010	Apr	CAHN
>A>	AB		1MG	A 077542	002	Aug 06, 2010	Apr	CAHN
>A>	AB		2MG	A 077542	003	Aug 06, 2010	Apr	CAHN
>A>	AB		3MG	A 078474	001	Aug 06, 2010	Apr	CAHN
>A>	AB		4MG	A 078474	002	Aug 06, 2010	Apr	CAHN

RIVAROXABANTABLET; ORAL
XARELTO

>D>	+	JANSSEN PHARMS	10MG	N 022406	001	Jul 01, 2011	Apr	CRLD
>A>			10MG	N 022406	001	Jul 01, 2011	Apr	CRLD

ROFLUMILASTTABLET; ORAL
DALIRESP

>	+	ASTRAZENECA PHARMS	500MCG	N 022522	001	Feb 28, 2011	Mar	CAHN
---	---	--------------------	--------	----------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDETABLET; ORAL
ROPINIROLE HYDROCHLORIDE

>A>	AB	G AND W LABS INC	EQ 0.25MG BASE	A 077460	001	May 05, 2008	Apr	CAHN
>A>	AB		EQ 0.5MG BASE	A 077460	002	May 05, 2008	Apr	CAHN
>A>	AB		EQ 1MG BASE	A 077460	003	May 05, 2008	Apr	CAHN
>A>	AB		EQ 2MG BASE	A 077460	004	May 05, 2008	Apr	CAHN
>A>	AB		EQ 3MG BASE	A 077460	005	May 05, 2008	Apr	CAHN
>A>	AB		EQ 4MG BASE	A 077460	006	May 05, 2008	Apr	CAHN
>A>	AB		EQ 5MG BASE	A 077460	007	May 19, 2008	Apr	CAHN
>D>	AB	TEVA	EQ 0.25MG BASE	A 077460	001	May 05, 2008	Apr	CAHN
>D>	AB		EQ 0.5MG BASE	A 077460	002	May 05, 2008	Apr	CAHN
>D>	AB		EQ 1MG BASE	A 077460	003	May 05, 2008	Apr	CAHN
>D>	AB		EQ 2MG BASE	A 077460	004	May 05, 2008	Apr	CAHN
>D>	AB		EQ 3MG BASE	A 077460	005	May 05, 2008	Apr	CAHN
>D>	AB		EQ 4MG BASE	A 077460	006	May 05, 2008	Apr	CAHN
>D>	AB		EQ 5MG BASE	A 077460	007	May 19, 2008	Apr	CAHN

SCOPOLAMINEFILM, EXTENDED RELEASE; TRANSDERMAL
SCOPOLAMINE

AB		PERRIGO PHARMS CO	1MG/72HR	A 078830	001	Jan 30, 2015	Mar	CAHN
AB		PERRIGO R AND D	1MG/72HR	A 078830	001	Jan 30, 2015	Jan	NEWA
AB	+	NOVARTIS	1MG/72HR	N 017874	001		Jan	CFTG

SELEGILINE HYDROCHLORIDETABLET; ORAL
SELEGILINE HYDROCHLORIDE

>A>		@ G AND W LABS INC	5MG	A 074537	001	Aug 02, 1996	Apr	CAHN
>A>		@	5MG	A 074744	001	Jan 27, 1997	Apr	CAHN
>A>		@	5MG	A 074756	001	Nov 25, 1998	Apr	CAHN
>D>		@ IVAX SUB TEVA PHARMS	5MG	A 074756	001	Nov 25, 1998	Apr	CAHN
>D>		@ TEVA	5MG	A 074537	001	Aug 02, 1996	Apr	CAHN
>D>		@	5MG	A 074744	001	Jan 27, 1997	Apr	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	RANBAXY	EQ 25MG BASE	A 077977	001	Feb 06, 2007	Apr	CAHN
>D>	AB		EQ 50MG BASE	A 077977	002	Feb 06, 2007	Apr	CAHN
>D>	AB		EQ 100MG BASE	A 077977	003	Feb 06, 2007	Apr	CAHN
>D>			EQ 150MG BASE	A 077977	004	Feb 06, 2007	Apr	CAHN
>D>			EQ 200MG BASE	A 077977	005	Feb 06, 2007	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	EQ 25MG BASE	A 077977	001	Feb 06, 2007	Apr	CAHN
>A>	AB		EQ 50MG BASE	A 077977	002	Feb 06, 2007	Apr	CAHN
>A>	AB		EQ 100MG BASE	A 077977	003	Feb 06, 2007	Apr	CAHN
>A>			EQ 150MG BASE	A 077977	004	Feb 06, 2007	Apr	CAHN
>A>			EQ 200MG BASE	A 077977	005	Feb 06, 2007	Apr	CAHN

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N 022473	001	Nov 18, 2009	Mar	CFTG
AP		AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A 203988	001	Apr 01, 2015	Mar	NEWA

SILDENAFIL CITRATE

CAPSULE; ORAL

RAPAFLO

+	ACTAVIS LABS UT INC	4MG	N 022206	001	Oct 08, 2008	Mar	CAHN
		8MG	N 022206	002	Oct 08, 2008	Mar	CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>D>	AB	RANBAXY	5MG	A 076285	001	Dec 20, 2006	Apr	CAHN
>D>	AB		10MG	A 076285	002	Dec 20, 2006	Apr	CAHN
>D>	AB		20MG	A 076285	003	Dec 20, 2006	Apr	CAHN
>D>	AB		40MG	A 076285	004	Dec 20, 2006	Apr	CAHN
>D>	AB		80MG	A 076285	005	Jun 23, 2006	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	5MG	A 076285	001	Dec 20, 2006	Apr	CAHN
>A>	AB		10MG	A 076285	002	Dec 20, 2006	Apr	CAHN
>A>	AB		20MG	A 076285	003	Dec 20, 2006	Apr	CAHN
>A>	AB		40MG	A 076285	004	Dec 20, 2006	Apr	CAHN
>A>	AB		80MG	A 076285	005	Jun 23, 2006	Apr	CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A 201850	001	Jan 20, 2012	Feb	CAHN
		SODIUM CHLORIDE 0.9%						
		EUROHLTH INTL SARL	9MG/ML	A 201833	001	Sep 24, 2013	Feb	CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
+		LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N 021569	001	Jul 27, 2006	Feb	CAHN
			112.5MG/125ML (9MG/ML)	N 021569	002	Jul 27, 2006	Feb	CAHN
+			405MG/50ML (9MG/ML)	N 021569	001	Jul 27, 2006	Feb	CPOT
			1012.5MG/125ML (9MG/ML)	N 021569	002	Jul 27, 2006	Feb	CPOT

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP		PRECISION NUCLEAR	10-200mCi/ML	A 204542	001	Feb 27, 2015	Feb	NEWA
>A>	AP	SPECTRON MRC LLC	10-200mCi/ML	A 203912	001	Apr 22, 2015	Apr	NEWA
>A>	AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A 204497	001	Apr 20, 2015	Apr	NEWA

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

>A>	AA	+	CARDINAL HEALTH 418	100uCi	N 018671	001	May 27, 1982	Apr	CAHN
>A>	AA	+		200uCi	N 018671	002	May 27, 1982	Apr	CAHN
>A>		@		400uCi	N 018671	003	May 27, 1982	Apr	CAHN
>D>	AA	+	CARDINAL HLTH 414	100uCi	N 018671	001	May 27, 1982	Apr	CAHN
>D>	AA	+		200uCi	N 018671	002	May 27, 1982	Apr	CAHN
>D>		@		400uCi	N 018671	003	May 27, 1982	Apr	CAHN

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar	NEWA	
		KAYEXALATE							
>A>	AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr	CAHN
>D>	AA	+	COVIS PHARMA SARL	453.6GM/BOT	N011287	001		Apr	CAHN

SOMATROPIN RECOMBINANTINJECTABLE; INJECTION
NORDITROPIN FLEXPRO

			NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan	NEWA
			NORDITROPIN NORDIFLEX						
			NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Mar	CMFD
			@	30MG/3ML	N021148	007	Mar 10, 2009	Jan	DISC
			NUTROPIN						
BX		+	GENENTECH	10MG/VIAL	N020168	002	Nov 17, 1993	Mar	CTEC
			ZOMACTON						
BX		+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar	CTNA
>D>	BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Apr	CRLD
>A>	BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr	CRLD
	BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar	NEWA

SOTALOL HYDROCHLORIDESOLUTION; INTRAVENOUS
SOTALOL HYDROCHLORIDE

>D>		+	ACADEMIC PHARMS	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr	CAHN
>A>		+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr	CAHN

TABLET; ORAL
BETAPACE

AB1			COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar	CAHN
AB1				120MG	N019865	005	Apr 20, 1994	Mar	CAHN
AB1		+		160MG	N019865	002	Oct 30, 1992	Mar	CAHN
AB1				240MG	N019865	003	Oct 30, 1992	Mar	CAHN
			@	320MG	N019865	004	Oct 30, 1992	Mar	CAHN

SULFACETAMIDE SODIUMLOTION; TOPICAL
KLARON

AB		+	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar	CAHN
----	--	---	----------------------	-----	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT			AKORN	10%	A040215	001	May 25, 1999	Mar	CMFD
----	--	--	-------	-----	---------	-----	--------------	-----	------

SULFANILAMIDECREAM; VAGINAL
SULFANILAMIDE

>A>			@ G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr	CAHN
>D>			@ TEVA	15%	A088718	001	Sep 19, 1985	Apr	CAHN

SUMATRIPTAN SUCCINATETABLET; ORAL
SUMATRIPTAN SUCCINATE

>D>	AB		RANBAXY	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr	CAHN
>D>	AB			EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr	CAHN
>D>	AB			EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr	CAHN
>A>	AB		SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr	CAHN
>A>	AB			EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr	CAHN
>A>	AB			EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr	CAHN

TELAPREVIRTABLET; ORAL
INCIVEK

			@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan	DISC
--	--	--	-----------------	-------	---------	-----	--------------	-----	------

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

>A>	AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
>A>	AB		20MG	A203691	002	May 08, 2015	Apr	NEWA
>A>	AB		100MG	A203691	003	May 08, 2015	Apr	NEWA
>A>	AB		140MG	A203691	004	May 08, 2015	Apr	NEWA
>A>	AB		180MG	A203691	005	May 08, 2015	Apr	NEWA
>A>	AB		250MG	A203691	006	May 08, 2015	Apr	NEWA

TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB		TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar	NEWA
AB	+	GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar	CFTG

TERBINAFINE HYDROCHLORIDETABLET;ORAL
TERBINAFINE HYDROCHLORIDE

@	WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC
---	-----------	---------------	---------	-----	--------------	-----	------

TESTOSTERONEGEL;TRANSDERMAL
ANDROGEL

AB1		ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC
AB1	+		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC
AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC
		TESTOSTERONE						
	@	ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
	@		1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
AB1		PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
AB1			50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC
		VOGELXO						
AB2		UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC

TETRABENAZINETABLET;ORAL
XENAZINE

		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Feb	CAHN
	+		25MG	N021894	002	Aug 15, 2008	Feb	CAHN

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
ACHROMYCIN V

>D>	AB	HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD
>A>	AB	+	500MG	N050278	001		Apr	CRLD
		TETRACYCLINE HYDROCHLORIDE						
>D>	AB	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC
>A>		@	250MG	A060704	001		Apr	DISC
>D>	AB	+	500MG	A060704	002		Apr	DISC
>A>		@	500MG	A060704	002		Apr	DISC

THEOPHYLLINETABLET;ORAL
THEOLAIR

@	MEDICIS	125MG	A086399	001		Mar	DISC
@		250MG	A086399	002		Mar	DISC

TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
ISTALOL

>D>	BT	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr	CFTG
>A>	AT2	+		EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr	CFTG
			TIMOLOL MALEATE						
>D>	AT		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr	CTEC
>A>	AT1			EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr	CTEC
>D>	AT			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr	CTEC
>A>	AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr	CTEC
>D>	AT		ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr	CTEC

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

>A>	AT1		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr	CTEC	
>A>	AT2	APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr	NEWA	
>D>	AT	BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr	CTEC	
>A>	AT1		EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr	CTEC	
>D>	AT	FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr	CTEC	
>A>	AT1		EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr	CTEC	
>D>	AT	HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr	CTEC	
>A>	AT1		EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr	CTEC	
>D>	AT	PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr	CTEC	
>A>	AT1		EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr	CTEC	
>D>	AT	WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CTEC	
>A>	AT1		EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CTEC	
<u>TIMOPTIC</u>									
>D>	AT	+ ATON	EQ 0.5% BASE	N018086	002		Apr	CTEC	
>A>	AT1	+	EQ 0.5% BASE	N018086	002		Apr	CTEC	

TOBRAMYCIN

SOLUTION; INHALATION
KITABIS PAK

AN PULMOFLOW INC 300MG/5ML N205433 001 Dec 02, 2014 Feb CTEC

SOLUTION/DROPS;OPHTHALMIC
TOBREX

AT + ALCON LABS INC 0.3% N050541 001 Mar CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

>D>	AP	AGILA SPECLTS	EQ 40MG BASE/ML	A065407	001	Mar 11, 2008	Apr	CAHN
		@ IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar	CAHN
		@	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar	CAHN
		@	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar	CAHN
		@	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar	CAHN
>A>	AP	MYLAN PHARMS INC	EQ 40MG BASE/ML	A065407	001	Mar 11, 2008	Apr	CAHN

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

>A>	@	G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
>A>	@		250MG	N018894	002	Nov 02, 1984	Apr	CAHN
>A>	@		500MG	N018894	003	Nov 02, 1984	Apr	CAHN
>D>	@	IVAX SUB TEVA PHARMS	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
>D>	@		250MG	N018894	002	Nov 02, 1984	Apr	CAHN
>D>	@		500MG	N018894	003	Nov 02, 1984	Apr	CAHN

TOLCAPONE

TABLET; ORAL
TASMAR

AB + VALEANT PHARMS LLC 100MG N020697 001 Jan 29, 1998 Mar CFTG

AB PAR PHARM INC 100MG A204584 001 Mar 26, 2015 Mar NEWA

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

>A>	@	G AND W LABS INC	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN
>D>	@	TEVA	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN

TOLTERODINE TARTRATE

TABLET; ORAL
TOLTERODINE TARTRATE

AB IVAX SUB TEVA PHARMS 1MG A077006 001 Feb 23, 2015 Feb NEWA

AB 2MG A077006 002 Feb 23, 2015 Feb NEWA

TOPIRAMATE

TABLET; ORAL
TOPIRAMATE

>D>	AB	RANBAXY	25MG	A076327	001	Mar 27, 2009	Apr	CAHN
>D>	AB		100MG	A076327	002	Mar 27, 2009	Apr	CAHN
>D>	AB		200MG	A076327	003	Mar 27, 2009	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr	CAHN

TABLET; ORAL
TOPIRAMATE

>A>	AB		100MG	A076327	002	Mar 27, 2009	Apr	CAHN
>A>	AB		200MG	A076327	003	Mar 27, 2009	Apr	CAHN
>D>	AB	WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr	DISC
>A>		@	25MG	A090353	001	Sep 01, 2010	Apr	DISC
>D>	AB		50MG	A090353	002	Sep 01, 2010	Apr	DISC
>A>		@	50MG	A090353	002	Sep 01, 2010	Apr	DISC
>D>	AB		100MG	A090353	003	Sep 01, 2010	Apr	DISC
>A>		@	100MG	A090353	003	Sep 01, 2010	Apr	DISC
>D>	AB		200MG	A090353	004	Sep 01, 2010	Apr	DISC
>A>		@	200MG	A090353	004	Sep 01, 2010	Apr	DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL
HYCAMTIN

		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar	CAHN
		+	EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar	CAHN
		INJECTABLE; INJECTION HYCAMTIN						
AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN

TORSEMIDE

INJECTABLE; INJECTION
TORSEMIDE

		@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan	DISC
		@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan	DISC
		@ LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan	DISC
		@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan	DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL
MEKINIST

		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN
			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN
		+	EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

>D>		@ FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD
>A>	AP		100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OLEPTRO

		@ ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar	DISC
		@	300MG	N022411	002	Feb 02, 2010	Mar	DISC

TRETINOIN

CREAM; TOPICAL
RENOVA

>D>	+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN	
>D>	AB2	+	0.05%	N019963	001	Dec 29, 1995	Apr	CAHN	
>A>	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN	
>A>	AB2	+	0.05%	N019963	001	Dec 29, 1995	Apr	CAHN	
		RETIN-A							
>D>	AB	+	VALEANT BERMUDA	0.1%	N017340	001		Apr	CAHN
>A>	AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

>D>		@ G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD
>A>	AT		0.025%	A089797	001	May 31, 1991	Apr	CMFD
>D>		@	0.1%	A089798	001	May 31, 1991	Apr	CMFD
>A>	AT		0.1%	A089798	001	May 31, 1991	Apr	CMFD
		TRIDERM						
AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA
AT			0.5%	A088042	003	Mar 25, 2015	Mar	NEWA

	LOTION;TOPICAL								
	TRIAMCINOLONE ACETONIDE								
AT	G AND W LABS INC	0.1%		A089129	001	Aug 14, 1986	Mar	CMFD	
	OINTMENT;TOPICAL								
	KENALOG								
AT	DELCOR ASSET CORP	0.025%		N011600	003		Mar	CMFD	
AT		0.1%		N011600	001		Mar	CMFD	
	SPRAY;TOPICAL								
	KENALOG								
AT	+ RANBAXY	0.147MG/GM		N012104	001		Mar	CFTG	
	TRIAMCINOLONE ACETONIDE								
AT	PERRIGO UK FINCO	0.147MG/GM		A205782	001	Apr 13, 2015	Mar	NEWA	
	<u>TRIAMTERENE</u>								
	CAPSULE;ORAL								
	DYRENIUM								
>A>	CONCORDIA PHARMS INC	50MG		N013174	001		Apr	CAHN	
>A>	+	100MG		N013174	002		Apr	CAHN	
>D>	COVIS PHARMA SARL	50MG		N013174	001		Apr	CAHN	
>D>	+	100MG		N013174	002		Apr	CAHN	
	<u>TRIPTORELIN PAMOATE</u>								
	INJECTABLE;INTRAMUSCULAR								
	TRELSTAR								
	+ ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL		N020715	001	Jun 15, 2000	Jan	CAHN	
	+	EQ 11.25MG BASE/VIAL		N021288	001	Jun 29, 2001	Jan	CAHN	
	+	EQ 22.5MG BASE/VIAL		N022437	001	Mar 10, 2010	Jan	CAHN	
	<u>TROSPIUM CHLORIDE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	TROSPIUM CHLORIDE								
>A> AB	SANDOZ INC	60MG		A091635	001	Apr 29, 2015	Apr	NEWA	
	<u>UNOPROSTONE ISOPROPYL</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	RESCULA								
	+ SUCAMPO PHARMA LLC	0.15%		N021214	001	Aug 03, 2000	Jan	CAHN	
	<u>URSODIOL</u>								
	CAPSULE;ORAL								
	ACTIGALL								
	@ ACTAVIS LABS UT INC	150MG		N019594	001	Dec 31, 1987	Mar	CAHN	
AB	+	300MG		N019594	002	Dec 31, 1987	Mar	CAHN	
	<u>VALACYCLOVIR HYDROCHLORIDE</u>								
	TABLET;ORAL								
	VALACYCLOVIR HYDROCHLORIDE								
AB	HETERO LABS LTD V	EQ 1GM BASE		A203047	002	Apr 08, 2015	Mar	NEWA	
AB		EQ 500MG BASE		A203047	001	Apr 08, 2015	Mar	NEWA	
>D> AB	RANBAXY	EQ 1GM BASE		A076588	002	Jan 31, 2007	Apr	CAHN	
>D> AB		EQ 500MG BASE		A076588	001	Jan 31, 2007	Apr	CAHN	
>A> AB	SUN PHARM INDS LTD	EQ 1GM BASE		A076588	002	Jan 31, 2007	Apr	CAHN	
>A> AB		EQ 500MG BASE		A076588	001	Jan 31, 2007	Apr	CAHN	
	<u>VALPROIC ACID</u>								
	CAPSULE;ORAL								
	VALPROIC ACID								
AB	BANNER LIFE SCIENCES	250MG		A073484	001	Jun 29, 1993	Jan	CAHN	
	CAPSULE, DELAYED RELEASE;ORAL								
	STAVZOR								
	@ BANNER LIFE SCIENCES	125MG		N022152	001	Jul 29, 2008	Jan	CAHN	
	@	250MG		N022152	002	Jul 29, 2008	Jan	CAHN	
	@	500MG		N022152	003	Jul 29, 2008	Jan	CAHN	
	<u>VANCOMYCIN HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	VANCOMYCIN HYDROCHLORIDE								
AB	LUPIN LTD	EQ 125MG BASE		A090439	001	Jan 28, 2015	Jan	NEWA	
AB		EQ 250MG BASE		A090439	002	Jan 28, 2015	Jan	NEWA	

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

>D>	AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Apr	CAHN
>D>	AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Apr	CAHN
>A>	AP	MYLAN PHARMS INC	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Apr	CAHN
>A>	AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Apr	CAHN

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

>D>	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr	CFTG
>A>	AB	+	10MG	N200179	001	Jun 17, 2010	Apr	CFTG
>A>		VARDENAFIL HYDROCHLORIDE						
>A>	AB	WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>D>	AP	AGILA SPECLTS	10MG/VIAL	A090243	001	May 11, 2010	Apr	CAHN
>D>	AP		20MG/VIAL	A090243	002	May 11, 2010	Apr	CAHN
>A>	AP	MYLAN PHARMS INC	10MG/VIAL	A090243	001	May 11, 2010	Apr	CAHN
>A>	AP		20MG/VIAL	A090243	002	May 11, 2010	Apr	CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb	CAHN
AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb	CAHN
AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

>D>	AB	ALKERMES GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr	CAHN
>D>	AB		180MG	N019614	003	Jan 09, 1992	Apr	CAHN
>D>	AB		240MG	N019614	002	May 29, 1990	Apr	CAHN
>D>	+		360MG	N019614	004	May 10, 1996	Apr	CAHN
>A>	AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr	CAHN
>A>	AB		180MG	N019614	003	Jan 09, 1992	Apr	CAHN
>A>	AB		240MG	N019614	002	May 29, 1990	Apr	CAHN
>A>	+		360MG	N019614	004	May 10, 1996	Apr	CAHN
		VERELAN PM						
>D>	AB	ALKERMES GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr	CAHN
>D>	AB		200MG	N020943	002	Nov 25, 1998	Apr	CAHN
>D>	AB	+	300MG	N020943	003	Nov 25, 1998	Apr	CAHN
>A>	AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr	CAHN
>A>	AB		200MG	N020943	002	Nov 25, 1998	Apr	CAHN
>A>	AB	+	300MG	N020943	003	Nov 25, 1998	Apr	CAHN

INJECTABLE; INJECTION

ISOPTIN

>D>		@ FSC	2.5MG/ML	N018485	001		Apr	CAHN
>A>		@ MT ADAMS	2.5MG/ML	N018485	001		Apr	CAHN

TABLET; ORAL

ISOPTIN

>D>		@ FSC	40MG	N018593	003	Nov 23, 1987	Apr	CAHN
>D>		@	80MG	N018593	001	Mar 08, 1982	Apr	CAHN
>D>		@	120MG	N018593	002	Mar 08, 1982	Apr	CAHN
>A>		@ MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr	CAHN
>A>		@	80MG	N018593	001	Mar 08, 1982	Apr	CAHN
>A>		@	120MG	N018593	002	Mar 08, 1982	Apr	CAHN

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+		VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN
---	--	--------------------	-----------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+		FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
			20MG	N022567	002	Jan 21, 2011	Mar	CAHN
			40MG	N022567	003	Jan 21, 2011	Mar	CAHN

ZAFIRLUKASTTABLET;ORAL
ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb	CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb	CAHN

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

>A>	AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr	NEWA
	AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
	AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT

ZOLPIDEM TARTRATETABLET;ORAL
ZOLPIDEM TARTRATE

	@	HIKMA	5MG	A078129	001	Apr 30, 2008	Mar	DISC
	@		10MG	A078129	002	Apr 30, 2008	Mar	DISC
>D>	AB	RANBAXY	5MG	A078055	001	Apr 23, 2007	Apr	CAHN
>D>	AB		10MG	A078055	002	Apr 23, 2007	Apr	CAHN
>A>	AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	CAHN
>A>	AB		10MG	A078055	002	Apr 23, 2007	Apr	CAHN

ZONISAMIDECAPSULE;ORAL
ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan	CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

>D>	@ RANBAXY	650MG	A 090205	001	Nov 18, 2009	Apr	CAHN
>D>	RANBAXY LABS LTD	650MG	A 078569	001	Dec 14, 2011	Apr	CAHN
>A>	SUN PHARM INDS LTD	650MG	A 078569	001	Dec 14, 2011	Apr	CAHN
>A>	@	650MG	A 090205	001	Nov 18, 2009	Apr	CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL
SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N 020045	001	Dec 07, 1992	Mar	CAHN
---	----------------------	------------	----------	-----	--------------	-----	------

BUDESONIDE

SPRAY, METERED;NASAL
RHINOCORT ALLERGY

+	ASTRAZENECA PHARMS	0.032MG/SPRAY	N 020746	003	Mar 23, 2015	Mar	NEWA
---	--------------------	---------------	----------	-----	--------------	-----	------

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL
LOTRIMIN ULTRA

+	BAYER HEALTHCARE LLC	1%	N 021307	001	Dec 07, 2001	Mar	CAHN
---	----------------------	----	----------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	BANNER LIFE SCIENCES	5MG	N 022429	001	Jul 23, 2009	Jan	CAHN
+		10MG	N 022429	004	Jul 23, 2009	Jan	CAHN
	BANNER LIFE SCIENCES	5MG	N 022429	003	Jul 23, 2009	Jan	CAHN
+		10MG	N 022429	002	Jul 23, 2009	Jan	CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	RANBAXY	5MG	A 077498	001	Dec 27, 2007	Apr	CAHN
>D>		10MG	A 077498	002	Dec 27, 2007	Apr	CAHN
>A>	SUN PHARM INDS LTD	5MG	A 077498	001	Dec 27, 2007	Apr	CAHN
>A>		10MG	A 077498	002	Dec 27, 2007	Apr	CAHN
	BANNER LIFE SCIENCES	5MG	N 022429	003	Jul 23, 2009	Jan	CAHN
>D>	RANBAXY	5MG	A 077498	003	Dec 27, 2007	Apr	CAHN
>D>		10MG	A 077498	004	Dec 27, 2007	Apr	CAHN
>A>	SUN PHARM INDS LTD	5MG	A 077498	003	Dec 27, 2007	Apr	CAHN
>A>		10MG	A 077498	004	Dec 27, 2007	Apr	CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	JUBILANT GENERICS	5MG	A 091116	001	Feb 19, 2015	Feb	NEWA
		10MG	A 091116	002	Feb 19, 2015	Feb	NEWA
	SANDOZ	5MG	A 078692	001	Feb 14, 2008	Feb	CTNA
+		10MG	A 078692	002	Feb 14, 2008	Feb	CTNA
	JUBILANT GENERICS	5MG	A 091116	003	Feb 19, 2015	Feb	NEWA
		10MG	A 091116	004	Feb 19, 2015	Feb	NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

@	BAYER HEALTHCARE LLC	8MG	N 007638	001		Mar	CAHN
+		12MG	N 007638	002		Mar	CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

+	BAYER HEALTHCARE LLC	8MG;120MG	N 018397	001		Mar	CAHN
---	----------------------	-----------	----------	-----	--	-----	------

CLOTRIMAZOLE

CREAM;VAGINAL
GYNE-LOTRIMIN

+	BAYER HEALTHCARE LLC	1%	N 018052	002	Nov 30, 1990	Mar	CAHN
	BAYER HEALTHCARE LLC	2%	N 020574	001	Nov 24, 1998	Mar	CAHN

CREAM, TABLET;TOPICAL, VAGINAL
GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,100MG N020289 002 Apr 26, 1993 Mar CAHN

TABLET;VAGINAL
GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 100MG N017717 002 Nov 30, 1990 Mar CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>D> RANBAXY 10MG A090283 001 Nov 17, 2009 Apr CAHN

>D> RANBAXY 20MG A090283 002 Nov 17, 2009 Apr CAHN

>A> SUN PHARM INDS LTD 10MG A090283 001 Nov 17, 2009 Apr CAHN

>A> SUN PHARM INDS LTD 20MG A090283 002 Nov 17, 2009 Apr CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL 60MG;120MG A090818 001 Jan 29, 2015 Jan NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES EQ 200MG FREE ACID AND POTASSIUM SALT A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES 200MG N021472 001 Oct 18, 2002 Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB EQ 0.035% BASE N021996 002 Feb 11, 2015 Feb NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES 1MG N021855 001 Aug 04, 2005 Jan CAHN

+ BANNER LIFE SCIENCES 2MG N021855 002 Aug 04, 2005 Jan CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

>D> RANBAXY 2MG;125MG A077500 001 Sep 06, 2006 Apr CAHN

>A> SUN PHARM INDS LTD 2MG;125MG A077500 001 Sep 06, 2006 Apr CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG N021952 001 Jun 16, 2008 Mar CAHN

SYRUP;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML N020641 003 Nov 19, 2003 Mar CAHN

TABLET;ORAL

LORATADINE

>D> RANBAXY 10MG A076134 001 Aug 18, 2003 Apr CAHN

>A> SUN PHARM INDS LTD 10MG A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG N021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS

+ BAYER HEALTHCARE LLC 5MG N021993 001 Dec 12, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
LORATADINE REDIDOSE

>D>	RANBAXY	10MG	A077153	001	Apr 11, 2007	Apr	CAHN
>A>	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007	Apr	CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
CLARITIN-D

	+ BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar	CAHN
	CLARITIN-D 24 HOUR						
	+ BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar	CAHN
	LORATADINE AND PSEUDOEPHEDRINE SULFATE						
>D>	RANBAXY	10MG;240MG	A076557	001	Sep 22, 2004	Apr	CAHN
>A>	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004	Apr	CAHN

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

	+ BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan	CAHN
	CATALENT	EQ 200MG BASE	A202807	001	Feb 13, 2015	Feb	NEWA
	TABLET;ORAL						
	NAPROXEN SODIUM						
>D>	RANBAXY LABS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr	CAHN
>A>	SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr	CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

@	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar	DISC
@		EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar	DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID OTC

	+ BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN
	FOR SUSPENSION;ORAL						
	ZEGERID OTC						
	+ BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	Mar	CAHN
--	----------------------	--------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
MIRALAX

	+ BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar	CAHN
	POLYETHYLENE GLYCOL 3350						
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	RANBAXY	120MG	A077442	001	Sep 28, 2005	Apr	CAHN
>A>	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005	Apr	CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

>D>	@ RANBAXY	EQ 75MG BASE	A075132	001	Jan 14, 2000	Apr	CAHN
>A>	@ SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000	Apr	CAHN
	@ WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008	Jan	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2015

NO APRIL 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8952065	Feb 10, 2035	U-1373			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	>A> 7223387	Jul 24, 2021	DP U-1006			
	>A> 7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	>A> 6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 003					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024		U-543		
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025		DP U-543		
	8338427	Mar 15, 2025		DP U-1633		
	8338428	Aug 06, 2023		DP U-543		
	8338428	Aug 06, 2023		DP U-1633		
>A>	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023		DP U-1530		
	8759351	Aug 06, 2023		DP U-1633		
>A>	8993761	Sep 25, 2022	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024		U-543		
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025		DP U-543		
	8338427	Mar 15, 2025		DP U-1633		
	8338428	Aug 06, 2023		DP U-543		
	8338428	Aug 06, 2023		DP U-1633		
>A>	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023		DP U-1530		
	8759351	Aug 06, 2023		DP U-1633		
>A>	8993761	Sep 25, 2022	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024		U-543		
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025		DP U-543		
	8338427	Mar 15, 2025		DP U-1633		
	8338428	Aug 06, 2023		DP U-543		
	8338428	Aug 06, 2023		DP U-1633		
>A>	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023		DP U-1530		
	8759351	Aug 06, 2023		DP U-1633		
>A>	8993761	Sep 25, 2022	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024		U-543		
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025		DP U-543		
	8338427	Mar 15, 2025		DP U-1633		
	8338428	Aug 06, 2023		DP U-543		
	8338428	Aug 06, 2023		DP U-1633		
>A>	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023		DP U-1530		
	8759351	Aug 06, 2023		DP U-1633		
>A>	8993761	Sep 25, 2022	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001 >A>	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002 >A>	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003 >A>	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004 >A>	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001 >A>	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002 >A>	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELECOXIB</u>						
A 078857	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	004				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	004				PC	Jun 02, 2015
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768	001	>A> 8062667	Mar 29, 2029	DP		
		>A> 8790700	Mar 15, 2027	DP		
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001	8371292	Feb 01, 2028	U-1356		
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001	8371292	Feb 01, 2028	U-1357		
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898	001				PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001	8962000	Aug 31, 2025	DP U-1410		
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395	001	5843946	Dec 01, 2015	DP U-1660		
		5843946*PED	Jun 01, 2016			
		7470506	Jun 23, 2019	U-1660		
		7470506*PED	Dec 23, 2019			
		7700645	Dec 26, 2026	DS DP		
		7700645*PED	Jun 26, 2027			
		8148374	Sep 03, 2029	DS DP U-1660		
		8518987	Feb 16, 2024	DS DP		
		8518987*PED	Aug 16, 2024			
		8597876	Jun 23, 2019	U-1660		
		8597876*PED	Dec 23, 2019			
		RE42889	Oct 19, 2016	DP		
		RE42889*PED	Apr 19, 2017			
		RE43596	May 09, 2017	DS DP		
		RE43596*PED	Nov 09, 2017			
		RE43802	Oct 19, 2016	U-1660		
		RE43802*PED	Apr 19, 2017			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	8981103	Oct 26, 2026	DS DP	I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820	001	8927607	Aug 22, 2033	U-1020		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	001	7230098	Aug 26, 2025	DS		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	002	7230098	Aug 26, 2025	DS		
<u>CROFELEMER - FULYZAQ</u>						
N 202292	001	8962680	Oct 31, 2031	U-1319		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	>A> 9006387	Jun 10, 2030	U-1687			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	>A> 6465504	Apr 05, 2019	DS DP			
	>A> 6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 002	>A> 6465504	Apr 05, 2019	DS DP			
	>A> 6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 003	>A> 6465504	Apr 05, 2019	DS DP			
	>A> 6596750	Jun 24, 2017	DS U-735			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	>A> 7622130	Dec 10, 2027	U-1690			
	>A> 7754230	Dec 10, 2027	U-1690			
	>A> 8101593	Mar 02, 2030	DP			
	>A> 8242294	May 16, 2028	DS			
	>A> 8298556	Aug 03, 2025	U-1690			
	>A> 8367649	Mar 02, 2030	DP			
	>A> 8461140	Feb 21, 2028	DP			
	>A> 8653058	Mar 02, 2030	DP			
	>A> 8846066	Feb 08, 2025	U-1690			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001 >A>	9011926	Feb 24, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002 >A>	9011926	Feb 24, 2026	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					>A> PC	Aug 01, 2015
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	>A> 9017721	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	>A> 9017721	Apr 23, 2030	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001 >A>	5061703	Apr 11, 2015	U-1641			
	>A> 5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	>A> 8168209	Nov 22, 2025	DP			
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-1641			
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-1641			
	>A> 8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002	>A> 5061703	Apr 11, 2015	U-1641		
		>A> 5061703*PED	Oct 11, 2015			
		>A> 8039009	Mar 24, 2029	U-1641		
		>A> 8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		>A> 8168209	Nov 22, 2025	DP		
		>A> 8168209*PED	May 22, 2026			
		>A> 8173708	Nov 22, 2025	U-1641		
		>A> 8173708*PED	May 22, 2026			
		>A> 8283379	Nov 22, 2025	U-1641		
		>A> 8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		>A> 8329752	Nov 22, 2025	DP		
		>A> 8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		>A> 8362085	Nov 22, 2025	U-1641		
		>A> 8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025	U-1641		
		>A> 8598233	Nov 22, 2025	DP		
		>A> 8598233*PED	May 22, 2026			
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795	006	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	001	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	003	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093	001	8981103	Oct 26, 2026	DS DP		
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093	002	8981103	Oct 26, 2026	DS DP		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	001	6303661	Apr 24, 2017	U-1651	NC	Jan 30, 2018
		6890898	Feb 02, 2019	U-1652	NCE	May 02, 2016
		7078381	Feb 02, 2019	U-1651	NCE	Aug 01, 2019
		7407955	Aug 12, 2023	DS DP		
		7459428	Feb 02, 2019	U-1651		
		7579449	Nov 05, 2025	DS		
		7713938	Apr 15, 2027	DS DP		
		8119648	Aug 12, 2023	U-1651		
		8178541	Aug 12, 2023	DP U-1653		
		8178541	Aug 12, 2023	DP U-1654		
		8551957	Oct 19, 2029	DP U-1651		
		8673927	May 04, 2027	DP U-1652		
		8846695	Jun 04, 2030	U-1652		
		8883805	Nov 26, 2025	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017				
	6890898	Feb 02, 2019		U-1651	NC	Jan 30, 2018
	7078381	Feb 02, 2019		U-1652	NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP	U-1651	NCE	Aug 01, 2019
	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		
	8178541	Aug 12, 2023	DP	U-1654		
	8551957	Oct 19, 2029	DP	U-1651		
	8673927	May 04, 2024	DP	U-1652		
	8846695	Jun 04, 2030		U-1652		
	8883805	Nov 26, 2025	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	8920377	Nov 23, 2024		DP		
	8926594	Mar 31, 2026		DP		
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	8920377	Nov 23, 2024		DP		
	8926594	Mar 31, 2026		DP		
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	>A> 6841716	Apr 27, 2020	DP			
	>A> 8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	>A> 9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	>A> 9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	>A> 9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	>A> 9006224	Jul 01, 2028	U-1681			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 6537983	Aug 03, 2021	DP U-1401		>A> I-708	Apr 30, 2018
	>A> 6537983	Aug 03, 2021	DP U-1691			
	>A> 6759398	Aug 03, 2021	DP U-1401			
	>A> 6759398	Aug 03, 2021	DP U-1691			
	>A> 7101866	Aug 03, 2021	DS DP U-1401			
	>A> 7101866	Aug 03, 2021	DS DP U-1691			
	>A> 7439393	Sep 11, 2022	DS DP U-1401			
	>A> 7439393	Sep 11, 2022	DS DP U-1691			
	>A> RE44874	Mar 23, 2023	DS DP U-1548			
	>A> RE44874	Mar 23, 2023	DS DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	>A> 5873360	Feb 23, 2016	DP		>A> NP	Apr 30, 2018
	>A> 6537983	Aug 03, 2021	DP U-1691			
	>A> 6759398	Aug 03, 2021	DP U-1691			
	>A> 7101866	Aug 03, 2021	DS DP U-1691			
	>A> 7439393	Sep 11, 2022	DS DP U-1691			
	>A> 7629335	Aug 03, 2021	DP			
	>A> 7776895	Sep 11, 2022	DP			
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8534281	Aug 10, 2029	DP			
	>A> 8746242	Oct 11, 2030	DP			
	>A> RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004					M-154	Mar 18, 2018
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	>A> 8999999	Jun 03, 2031	U-1683			
	>A> 8999999	Jun 03, 2031	U-1684			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	>A> 8871810	Sep 30, 2029	U-1599			
	>A> 9012508	Sep 14, 2030	U-981			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8980901	May 12, 2025	U-1678			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8980901	May 12, 2025	U-1678			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	>A> 8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	>A> 8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	>A> 8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004 >A>	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005 >A>	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006 >A>	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007 >A>	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	>A> 9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	>A> 9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	>A> 9011391	Mar 26, 2024	DP			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2016	DS			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		GAIN	Mar 06, 2025
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		GAIN	Mar 06, 2025
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	>A> 7361649	Apr 17, 2026	DS DP U-1694		>A> NCE	Apr 15, 2020
	>A> 7361650	Apr 14, 2026	DS DP U-1694			
	>A> 7867996	Feb 22, 2026	DS DP U-1694			
	>A> 7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	>A> 7361649	Apr 17, 2026	DS DP U-1694		>A> NCE	Apr 15, 2020
	>A> 7361650	Apr 14, 2026	DS DP U-1694			
	>A> 7867996	Feb 22, 2026	DS DP U-1694			
	>A> 7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	>A> 5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	>A> 5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	>A> 5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	>A> 5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	>A> 6004968	Mar 20, 2018	DP U-248			
	>A> 6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-1663			
	7435734	Oct 21, 2022	U-1663			
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828	003				PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828	004				PC	Sep 28, 2015
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	001	8980327	Dec 01, 2030	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	002	8980327	Dec 01, 2030	DP		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	001				I-706 >A> ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	002				I-706 >A> ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	003				I-706 >A> ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	004				I-706 >A> ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	005				I-706 >A> ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	006	5635517	Oct 04, 2019	DS U-1211	I-706 >A> ODE	Feb 17, 2018 Feb 17, 2022
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947	001	7253286	Oct 19, 2021	DS DP	NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP	ODE	Feb 13, 2022
	>A>	9006256	Jul 27, 2027	U-1695		
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947	002	7253286	Oct 19, 2021	DS DP	NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP	ODE	Feb 13, 2022
	>A>	9006256	Jul 27, 2027	U-1695		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	003	7429559	Jan 13, 2019	DP		
		8815801	Jun 28, 2022	DP		
		8921326	Feb 05, 2031	DP U-1666		
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	001				M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	002				M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	003				M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	004				M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001				M-156	Mar 12, 2018
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417	001	8163306	Sep 03, 2027	DP		
		8425938	Feb 22, 2026	DP		
		8431156	Oct 31, 2027	DP		
		8470367	Jun 30, 2024	DP		
		8535717	Feb 22, 2026	DP		
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417	002	8163306	Sep 03, 2027	DP		
		8425938	Feb 22, 2026	DP		
		8431156	Oct 31, 2027	DP		
		8470367	Jun 30, 2024	DP		
		8535717	Feb 22, 2026	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563	001				>A> PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563	002				>A> PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229	001				NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	001	9006289	Oct 03, 2032	DP		
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	002	9006289	Oct 03, 2032	DP		
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	003	9006289	Oct 03, 2032	DP		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	001	8933030	Feb 17, 2031	DP		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	002	8933030	Feb 17, 2031	DP		
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280	001	8673927	May 04, 2027	U-1503		
		8853156	Mar 05, 2031	U-1642		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281	001	8673927	May 04, 2027	U-1503		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281	002	8673927	May 04, 2027	U-1503		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281	003	8673927	May 04, 2027	U-1503		
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341	001	8846618	Jun 27, 2022	DP		
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321	001	6268343	Aug 22, 2022	DS DP	U-1255	
		6458924	Aug 22, 2017	DS DP	U-1255	
		6899699	Jan 01, 2022	DP		
		7235627	Aug 22, 2017	DS DP		
	>A>	7686786	Aug 03, 2026	DP		
		8114833	Aug 13, 2025	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8846618	Jun 27, 2022	DP		
		8920383	Jul 17, 2026	DP		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	001				I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	002				I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	003				I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	004				I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	005				I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	006				I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	007				I-703	Jan 30, 2018
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	001	5712279	Feb 21, 2016	DS	U-1317	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	002	5712279	Feb 21, 2016	DS	U-1317	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	003	5712279	Feb 21, 2016	DS	U-1317	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
>A>	8999970	Feb 07, 2033	U-1688			
>A>	8999970	Feb 07, 2033	U-1689			
>A>	8999970	Feb 07, 2033	U-1692			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
>A>	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
>A>	9012484	Sep 06, 2033	DS DP U-540			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	>A> 9000038	Jul 31, 2017	U-666			
	>A> 9000038	Jul 31, 2017	U-1693			
	>A> 9000038*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	>A> 9000038	Jul 31, 2017	U-666			
	>A> 9000038	Jul 31, 2017	U-1693			
	>A> 9000038*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	>A> 9000038	Jul 31, 2017	U-666			
	>A> 9000038	Jul 31, 2017	U-1693			
	>A> 9000038*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	>A> 9000038	Jul 31, 2017	U-666			
	>A> 9000038	Jul 31, 2017	U-1693			
	>A> 9000038*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001					>A> NP	Apr 17, 2018
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002					>A> NP	Apr 17, 2018
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003					>A> NP	Apr 17, 2018
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004					>A> NP	Apr 17, 2018
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005					>A> NP	Apr 17, 2018
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006					>A> NP	Apr 17, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	007				>A> NP	Apr 17, 2018
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223	001	>A> 7893097	Feb 19, 2028	DP		
		>A> 8658678	Jun 27, 2028		U-1682	
		>A> 8877792	Feb 02, 2028	DP		
		8946276	Jun 28, 2032		U-1664	
<u>MIFEPRISTONE - KORLYM</u>						
N 202107	001	8921348	Aug 27, 2028		U-1643	
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781	001	7699609	Mar 29, 2022	DP		
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812	002	6946120	Apr 20, 2019	DP	U-702	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	001	8623418	Nov 07, 2029		U-1640	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	002	8623418	Nov 07, 2029		U-1640	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	003	8623418	Nov 07, 2029		U-1640	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	004	8623418	Nov 07, 2029		U-1640	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	005	8623418	Nov 07, 2029		U-1640	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	006	8623418	Nov 07, 2029		U-1640	
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787	001	8926594	Mar 31, 2026	DP		
		8939943	Feb 28, 2031	DP		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	001	8969369	May 10, 2022	DP	U-1556	
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	002	8969369	May 10, 2022	DP	U-1556	
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	003	8969369	May 10, 2022	DP	U-1556	
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	001	6060499	Aug 14, 2017	DP	U-867	
		6060499*PED	Feb 14, 2018			
		6586458	Aug 14, 2017	DP	U-867	
		6586458*PED	Feb 14, 2018			
		7332183	Oct 02, 2025	DP	U-867	
		7332183*PED	Apr 02, 2026			
		8022095	Aug 14, 2017	DP	U-867	
		8022095*PED	Feb 14, 2018			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	8951969	Nov 18, 2030	DP		
<u>NICOTINE - NICODERM CQ</u>						
N 020165	004	>A> 8999379	Feb 13, 2020		U-1686	
<u>NICOTINE - NICODERM CQ</u>						
N 020165	005	>A> 8999379	Feb 13, 2020		U-1686	
<u>NICOTINE - NICODERM CQ</u>						
N 020165	006	>A> 8999379	Feb 13, 2020		U-1686	
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001	8940772	Apr 30, 2029	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002	8940772	Apr 30, 2029	DP		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001	7989474	Apr 06, 2024		U-1677	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
<u>LOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001 >A>	8642079	Jul 09, 2028	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007					M-153	Apr 16, 2016
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP	U-904		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001	>A> 9011905	Jun 09, 2028	DP			
	>A> 9011906	Jun 09, 2028		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002	>A> 9011905	Jun 09, 2028	DP			
	>A> 9011906	Jun 09, 2028		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003	>A> 9011905	Jun 09, 2028	DP			
	>A> 9011906	Jun 09, 2028		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004	>A> 9011905	Jun 09, 2028	DP			
	>A> 9011906	Jun 09, 2028		U-1262		
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027		U-1601		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					>A> I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					>A> I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					>A> I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					>A> I-707	Apr 23, 2018
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8946252	Jul 24, 2029		U-1481		
	8969398	Oct 02, 2029		U-1481		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2016	DS DP	U-1115		
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019		U-1101		
	8952062	Dec 22, 2019		U-1102		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP	U-1670	M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP	U-1328		
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP	U-1320		
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	>A> 8435944	Sep 27, 2027		U-1390		
	8993520	Jun 02, 2026		U-1390		
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8992989	Nov 16, 2027	DP	U-1675		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8992989	Nov 16, 2027	DP U-1675			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001 >A>	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002 >A>	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003 >A>	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004 >A>	7417070	Jul 30, 2026	DS			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003 >A>	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030	U-1657			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					>A> D-148	Apr 23, 2018
					>A> NPP	Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					>A> D-148	Apr 23, 2018
					>A> NPP	Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8969355	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>